<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="pt" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="pmc-domain-id">2391</journal-id><journal-id journal-id-type="pmc-domain">arqbrascard</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11634293</article-id><article-id pub-id-type="pmcid-ver">PMC11634293.1</article-id><article-id pub-id-type="pmcaid">11634293</article-id><article-id pub-id-type="pmcaiid">11634293</article-id><article-id pub-id-type="pmid">39607170</article-id><article-id pub-id-type="doi">10.36660/abc.20240202</article-id><article-id pub-id-type="other">00306</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Artigo Original</subject></subj-group></article-categories><title-group><article-title>Terapia Antiplaquet&#225;ria Dupla Combinada em Pacientes com Doen&#231;a Arterial Coronariana em uma Popula&#231;&#227;o na Turquia: DAPT-TR</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0268-9641</contrib-id><name name-style="western"><surname>&#214;z</surname><given-names initials="A">Ahmet</given-names></name><role>Concep&#231;&#227;o e desenho da pesquisa</role><role>An&#225;lise e interpreta&#231;&#227;o dos dados</role><role>An&#225;lise estat&#237;stica e Reda&#231;&#227;o do manuscrito</role><role>Obten&#231;&#227;o de dados</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8923-8709</contrib-id><name name-style="western"><surname>Toprak</surname><given-names initials="K">Kenan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7280-5137</contrib-id><name name-style="western"><surname>Aydin</surname><given-names initials="E">Ertan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1574-2053</contrib-id><name name-style="western"><surname>Sara&#231;</surname><given-names initials="&#x130;">&#304;brahim</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3895-1923</contrib-id><name name-style="western"><surname>Do&#287;du&#351;</surname><given-names initials="M">Mustafa</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6335-5250</contrib-id><name name-style="western"><surname>Opan</surname><given-names initials="S">Sel&#231;uk</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0933-7852</contrib-id><name name-style="western"><surname>Yener&#231;a&#287;</surname><given-names initials="M">Mustafa</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9008-6631</contrib-id><name name-style="western"><surname>Tascanov</surname><given-names initials="MB">Mustafa Begenc</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5369-5414</contrib-id><name name-style="western"><surname>K&#252;met</surname><given-names initials="&#xD6;">&#214;mer</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5688-6977</contrib-id><name name-style="western"><surname>Karaa&#287;a&#231;</surname><given-names initials="M">Mira&#231;</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6237-1398</contrib-id><name name-style="western"><surname>&#214;zmen</surname><given-names initials="M">Murat</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6564-7185</contrib-id><name name-style="western"><surname>Murat</surname><given-names initials="B">Bekta&#351;</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9951-2617</contrib-id><name name-style="western"><surname>Kertmen</surname><given-names initials="&#xD6;">&#214;mer</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0031-6457</contrib-id><name name-style="western"><surname>Bekler</surname><given-names initials="&#xD6;">&#214;zkan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4576-128X</contrib-id><name name-style="western"><surname>&#304;nci</surname><given-names initials="S">Sinan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8740-1429</contrib-id><name name-style="western"><surname>Huyut</surname><given-names initials="MA">Mustafa Ahmet</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4369-6146</contrib-id><name name-style="western"><surname>&#214;zderya</surname><given-names initials="A">Ahmet</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5016-5511</contrib-id><name name-style="western"><surname>Er</surname><given-names initials="F">Fahri</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5937-235X</contrib-id><name name-style="western"><surname>Duran</surname><given-names initials="M">Mustafa</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9309-803X</contrib-id><name name-style="western"><surname>Ardahanl&#305;</surname><given-names initials="&#x130;">&#304;sa</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff18" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0895-7371</contrib-id><name name-style="western"><surname>Ba&#351;</surname><given-names initials="MM">Mehmet Memduh</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff19" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8470-1928</contrib-id><name name-style="western"><surname>G&#252;zel</surname><given-names initials="T">Tuncay</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff20" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6965-5713</contrib-id><name name-style="western"><surname>Ceyhun</surname><given-names initials="G">G&#246;khan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff21" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3953-4387</contrib-id><name name-style="western"><surname>&#214;zdemir</surname><given-names initials="&#x130;H">&#304;brahim Halil</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff22" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9499-3466</contrib-id><name name-style="western"><surname>&#214;zen</surname><given-names initials="MB">Mehmet Burak</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff22" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7133-4604</contrib-id><name name-style="western"><surname>G&#252;nd&#252;z</surname><given-names initials="R">Ramazan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff22" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1094-5572</contrib-id><name name-style="western"><surname>Erdo&#287;an</surname><given-names initials="A">Aslan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff23" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0331-9167</contrib-id><name name-style="western"><surname>&#199;etin</surname><given-names initials="&#x130;">&#304;lyas</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff23" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3021-8612</contrib-id><name name-style="western"><surname>Bar&#305;&#351;</surname><given-names initials="V&#xD6;">Veysel &#214;zg&#252;r</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff24" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5302-4052</contrib-id><name name-style="western"><surname>Yayla</surname><given-names initials="&#xC7;">&#199;a&#287;r&#305;</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff25" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6080-6335</contrib-id><name name-style="western"><surname>Karaduman</surname><given-names initials="M">Medeni</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff26" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7768-2562</contrib-id><name name-style="western"><surname>A&#351;k&#305;n</surname><given-names initials="L">L&#252;tf&#252;</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff27" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3920-1382</contrib-id><name name-style="western"><surname>Bekar</surname><given-names initials="L">L&#252;tf&#252;</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff28" ref-type="aff">
<sup>28</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3531-8409</contrib-id><name name-style="western"><surname>Tanr&#305;verdi</surname><given-names initials="O">Okan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff29" ref-type="aff">
<sup>29</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0792-628X</contrib-id><name name-style="western"><surname>&#214;zkan</surname><given-names initials="E">Ey&#252;p</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff23" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4102-444X</contrib-id><name name-style="western"><surname>Ye&#351;il</surname><given-names initials="E">Emrah</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff30" ref-type="aff">
<sup>30</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0260-5463</contrib-id><name name-style="western"><surname>&#199;al&#305;&#351;kan</surname><given-names initials="S">Serhat</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff31" ref-type="aff">
<sup>31</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5378-5516</contrib-id><name name-style="western"><surname>Kuzu</surname><given-names initials="Z">Z&#252;lfiye</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff32" ref-type="aff">
<sup>32</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4834-5572</contrib-id><name name-style="western"><surname>U&#287;uz</surname><given-names initials="B">Berat</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff33" ref-type="aff">
<sup>33</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2313-1495</contrib-id><name name-style="western"><surname>B&#246;y&#252;k</surname><given-names initials="F">Ferit</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff34" ref-type="aff">
<sup>34</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8930-3651</contrib-id><name name-style="western"><surname>Kunak</surname><given-names initials="A&#xDC;">Ay&#351;eg&#252;l &#220;lgen</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff35" ref-type="aff">
<sup>35</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3935-0222</contrib-id><name name-style="western"><surname>Murat</surname><given-names initials="S">Selda</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff36" ref-type="aff">
<sup>36</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6782-4237</contrib-id><name name-style="western"><surname>Asil</surname><given-names initials="S">Serkan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff37" ref-type="aff">
<sup>37</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0379-7812</contrib-id><name name-style="western"><surname>Kayhan</surname><given-names initials="&#xD6;">&#214;zkan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff38" ref-type="aff">
<sup>38</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2329-6310</contrib-id><name name-style="western"><surname>Erdo&#287;an</surname><given-names initials="E">Emrah</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff39" ref-type="aff">
<sup>39</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5022-4040</contrib-id><name name-style="western"><surname>Duz</surname><given-names initials="R">Ramazan</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff39" ref-type="aff">
<sup>39</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6818-0106</contrib-id><name name-style="western"><surname>Katkat</surname><given-names initials="F">Fahrettin</given-names></name><role> Obten&#231;&#227;o de dados</role><xref rid="aff40" ref-type="aff">
<sup>40</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4015-1711</contrib-id><name name-style="western"><surname>Ekin</surname><given-names initials="T">Tuba</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff41" ref-type="aff">
<sup>41</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1231-0933</contrib-id><name name-style="western"><surname>&#304;bi&#351;o&#287;lu</surname><given-names initials="E">Ersin</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff23" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9531-8350</contrib-id><name name-style="western"><surname>Ate&#351;</surname><given-names initials="BN">Bilge Nazar</given-names></name><role>Obten&#231;&#227;o de dados</role><xref rid="aff42" ref-type="aff">
<sup>42</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9901-9419</contrib-id><name name-style="western"><surname>Ay&#231;a</surname><given-names initials="B">Burak</given-names></name><role>Concep&#231;&#227;o e desenho da pesquisa</role><role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role><xref rid="aff40" ref-type="aff">
<sup>40</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1775-4063</contrib-id><name name-style="western"><surname>Ergene</surname><given-names initials="AO">As&#305;m Oktay</given-names></name><role>Concep&#231;&#227;o e desenho da pesquisa</role><role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role><xref rid="aff43" ref-type="aff">
<sup>43</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8156-2675</contrib-id><name name-style="western"><surname>Zoghi</surname><given-names initials="M">Mehdi</given-names></name><role>Concep&#231;&#227;o e desenho da pesquisa</role><role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do</role><xref rid="aff44" ref-type="aff">
<sup>44</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<institution content-type="orgname">Health Science University</institution>
<institution content-type="orgdiv1"> Istanbul Training and Research Hospital</institution>
<addr-line><named-content content-type="city">Istanbul</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Department of Cardiology, Health Science University, Istanbul Training and Research Hospital, Istanbul - Turquia</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">Harran University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Sanliurfa</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Harran University, Faculty of Medicine, Department of Cardiology, Sanliurfa - Turquia</institution>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="orgname">Giresun Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Giresun</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Giresun Training and Research Hospital, Department of Cardiology, Giresun - Turquia</institution>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="orgname">Erzurum City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Erzurum</named-content></addr-line>
<country country="TR">Turkey</country>
<institution content-type="original">Erzurum City Hospital, Department of Cardiology, Erzurum - Turkey</institution>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="orgname">U&#351;ak University</institution>
<institution content-type="orgdiv1">Training and Research Hospital</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Usak</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">U&#351;ak University Training and Research Hospital, Department of Cardiology, Usak - Turquia</institution>
</aff><aff id="aff6">
<label>6</label>
<institution content-type="orgname">Sanliurfa Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#350;anl&#305;urfa</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Sanliurfa Training and Research Hospital, Department of Cardiology, &#350;anl&#305;urfa - Turquia</institution>
</aff><aff id="aff7">
<label>7</label>
<institution content-type="orgname">Samsun University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Samsun</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Samsun University, Faculty of Medicine, Department of Cardiology, Samsun - Turquia</institution>
</aff><aff id="aff8">
<label>8</label>
<institution content-type="orgname">Van Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Van</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Van Training and Research Hospital, Department of Cardiology, Van - Turquia</institution>
</aff><aff id="aff9">
<label>9</label>
<institution content-type="orgname">&#304;n&#246;n&#252; University Turgut &#214;zal T&#305;p Merkezi</institution>
<institution content-type="orgdiv1">Training and Research Hospital</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Malatya</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">&#304;n&#246;n&#252; University Turgut &#214;zal T&#305;p Merkezi Training and Research Hospital, Department of Cardiology, Malatya - Turquia</institution>
</aff><aff id="aff10">
<label>10</label>
<institution content-type="orgname">Eski&#351;ehir City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Eski&#351;ehir</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Eski&#351;ehir City Hospital, Department of Cardiology, Eski&#351;ehir - Turquia</institution>
</aff><aff id="aff11">
<label>11</label>
<institution content-type="orgname">Amasya University Sabuncuo&#287;lu &#350;erefeddin</institution>
<institution content-type="orgdiv1">Training and Research Hospital</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Amasya</named-content></addr-line>
<country country="TR">Turquia </country>
<institution content-type="original">Amasya University Sabuncuo&#287;lu &#350;erefeddin Training and Research Hospital, Department of Cardiology, Amasya - Turquia </institution>
</aff><aff id="aff12">
<label>12</label>
<institution content-type="orgname">Mustafa Kemal University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Hatay</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Mustafa Kemal University, Faculty of Medicine, Department of Cardiology, Hatay - Turquia</institution>
</aff><aff id="aff13">
<label>13</label>
<institution content-type="orgname">Aksaray University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Aksaray</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Aksaray University, Faculty of Medicine, Department of Cardiology, Aksaray - Turquia</institution>
</aff><aff id="aff14">
<label>14</label>
<institution content-type="orgname">&#304;stanbul Prof.Dr.Cemil Ta&#351;c&#305;o&#287;lu City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#304;stanbul</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">&#304;stanbul Prof.Dr.Cemil Ta&#351;c&#305;o&#287;lu City Hospital, Department of Cardiology, &#304;stanbul - Turquia</institution>
</aff><aff id="aff15">
<label>15</label>
<institution content-type="orgname">Trabzon Kanuni Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology,</institution>
<addr-line><named-content content-type="city">Trabzon</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Trabzon Kanuni Training and Research Hospital, Department of Cardiology, Trabzon - Turquia</institution>
</aff><aff id="aff16">
<label>16</label>
<institution content-type="orgname">A&#287;r&#305; Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology,</institution>
<addr-line><named-content content-type="city">A&#287;r&#305;</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">A&#287;r&#305; Training and Research Hospital, Department of Cardiology, A&#287;r&#305; - Turquia</institution>
</aff><aff id="aff17">
<label>17</label>
<institution content-type="orgname">Konya City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Konya</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Konya City Hospital, Department of Cardiology, Konya - Turquia</institution>
</aff><aff id="aff18">
<label>18</label>
<institution content-type="orgname">Bilcecik &#350;eyh Edebali University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Bilecik</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Bilcecik &#350;eyh Edebali University, Faculty of Medicine, Department of Cardiology, Bilecik - Turquia</institution>
</aff><aff id="aff19">
<label>19</label>
<institution content-type="orgname">Private Meydan Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#350;anl&#305;urfa</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Private Meydan Hospital, Department of Cardiology, &#350;anl&#305;urfa - Turquia</institution>
</aff><aff id="aff20">
<label>20</label>
<institution content-type="orgname">Gazi Ya&#351;argil Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Diyarbak&#305;r</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Gazi Ya&#351;argil Training and Research Hospital, Department of Cardiology, Diyarbak&#305;r - Turquia</institution>
</aff><aff id="aff21">
<label>21</label>
<institution content-type="orgname">Atat&#252;rk University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Erzurum</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Atat&#252;rk University, Faculty of Medicine, Department of Cardiology, Erzurum - Turquia</institution>
</aff><aff id="aff22">
<label>22</label>
<institution content-type="orgname">Manisa City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Manisa</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Manisa City Hospital, Department of Cardiology, Manisa - Turquia</institution>
</aff><aff id="aff23">
<label>23</label>
<institution content-type="orgname">Ba&#351;ak&#351;ehir &#199;am ve Sakura City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#304;stanbul</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Ba&#351;ak&#351;ehir &#199;am ve Sakura City Hospital, Department of Cardiology, &#304;stanbul - Turquia</institution>
</aff><aff id="aff24">
<label>24</label>
<institution content-type="orgname">Gaziantep Dr. Ersin Arslan Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Gaziantep</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Gaziantep Dr. Ersin Arslan Training and Research Hospital, Department of Cardiology, Gaziantep - Turquia</institution>
</aff><aff id="aff25">
<label>25 </label>
<institution content-type="orgname">Ankara Bilkent City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Ankara</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Ankara Bilkent City Hospital, Department of Cardiology,Ankara &#8211; Turquia</institution>
</aff><aff id="aff26">
<label>26</label>
<institution content-type="orgname">Van Y&#252;z&#252;nc&#252; Y&#305;l University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Van</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Van Y&#252;z&#252;nc&#252; Y&#305;l University, Faculty of Medicine, Department of Cardiology, Van - Turquia</institution>
</aff><aff id="aff27">
<label>27</label>
<institution content-type="orgname">Gaziantep &#304;slam Bilim ve Teknoloji University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Gaziantep</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Gaziantep &#304;slam Bilim ve Teknoloji University, Faculty of Medicine, Department of Cardiology, Gaziantep - Turquia</institution>
</aff><aff id="aff28">
<label>28</label>
<institution content-type="orgname">Hitit University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#199;orum</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Hitit University, Faculty of Medicine, Department of Cardiology, &#199;orum - Turquia</institution>
</aff><aff id="aff29">
<label>29</label>
<institution content-type="orgname">Ad&#305;yaman University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Ad&#305;yaman</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Ad&#305;yaman University, Faculty of Medicine, Department of Cardiology, Ad&#305;yaman &#8211; Turquia</institution>
</aff><aff id="aff30">
<label>30</label>
<institution content-type="orgname">Mersin University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Mersin</named-content></addr-line>
<country country="TR">Turquia </country>
<institution content-type="original">Mersin University, Faculty of Medicine, Department of Cardiology, Mersin - Turquia </institution>
</aff><aff id="aff31">
<label>31 </label>
<institution content-type="orgname">Bah&#231;elievler State Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#304;stanbul</named-content></addr-line>
<country country="TR">Turquia </country>
<institution content-type="original">Bah&#231;elievler State Hospital, Department of Cardiology,&#304;stanbul - Turquia </institution>
</aff><aff id="aff32">
<label>32</label>
<institution content-type="orgname">Kayseri City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Kayseri</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Kayseri City Hospital, Department of Cardiology, Kayseri - Turquia</institution>
</aff><aff id="aff33">
<label>33</label>
<institution content-type="orgname">Bursa City Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Bursa</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Bursa City Hospital, Department of Cardiology, Bursa - Turquia</institution>
</aff><aff id="aff34">
<label>34</label>
<institution content-type="orgname">Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#304;stanbul</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Cardiology, &#304;stanbul - Turquia</institution>
</aff><aff id="aff35">
<label>35</label>
<institution content-type="orgname">Band&#305;rma Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Bal&#305;kesir</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Band&#305;rma Training and Research Hospital, Department of Cardiology, Bal&#305;kesir - Turquia</institution>
</aff><aff id="aff36">
<label>36</label>
<institution content-type="orgname">Eski&#351;ehir Osmangazi University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Eski&#351;ehir</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Eski&#351;ehir Osmangazi University, Faculty of Medicine, Department of Cardiology, Eski&#351;ehir - Turquia</institution>
</aff><aff id="aff37">
<label>37</label>
<institution content-type="orgname">G&#252;lhane Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Ankara</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">G&#252;lhane Training and Research Hospital, Department of Cardiology, Ankara - Turquia</institution>
</aff><aff id="aff38">
<label>38</label>
<institution content-type="orgname">Kepez State Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Antalya</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Kepez State Hospital, Department of Cardiology, Antalya - Turquia</institution>
</aff><aff id="aff39">
<label>39</label>
<institution content-type="orgname">Van Y&#252;z&#252;nc&#252; Y&#305;l University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Van</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Van Y&#252;z&#252;nc&#252; Y&#305;l University, Faculty of Medicine, Department of Cardiology, Van - Turquia</institution>
</aff><aff id="aff40">
<label>40</label>
<institution content-type="orgname">&#304;stanbul Training and Research Hospital</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">&#304;stanbul</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">&#304;stanbul Training and Research Hospital, Department of Cardiology, &#304;stanbul - Turquia</institution>
</aff><aff id="aff41">
<label>41</label>
<institution content-type="orgname">K&#305;r&#351;ehir Ahi Evran University</institution>
<institution content-type="orgdiv1">Training and Research Hospital</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">K&#305;r&#351;ehir</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">K&#305;r&#351;ehir Ahi Evran University Training and Research Hospital, Department of Cardiology, K&#305;r&#351;ehir - Turquia</institution>
</aff><aff id="aff42">
<label>42</label>
<institution content-type="orgname">Ankara University</institution>
<institution content-type="orgdiv1">Faculty of Medicine</institution>
<institution content-type="orgdiv2">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Ankara</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Ankara University, Faculty of Medicine, Department of Cardiology, Ankara - Turquia</institution>
</aff><aff id="aff43">
<label>43</label>
<institution content-type="orgname">Dokuz Eylul University</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Izmir</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Dokuz Eylul University, Department of Cardiology, Izmir - Turquia</institution>
</aff><aff id="aff44">
<label>44</label>
<institution content-type="orgname">Ege University</institution>
<institution content-type="orgdiv1">Department of Cardiology</institution>
<addr-line><named-content content-type="city">Izmir</named-content></addr-line>
<country country="TR">Turquia</country>
<institution content-type="original">Ege University, Department of Cardiology, Izmir - Turquia</institution>
</aff><author-notes><corresp id="c01"><label>Correspond&#234;ncia:</label> Ahmet &#214;z &#8226; Istanbul Training and Research Hospital - &#304;stanbul Istanbul 34100 - Turquia; E-mail: <email>drozahmet@gmail.com</email></corresp><fn fn-type="edited-by"><p><bold>Editor respons&#225;vel pela revis&#227;o:</bold> Gl&#225;ucia Maria Moraes de Oliveira</p></fn><fn fn-type="COI-statement"><p><bold>Potencial conflito de interesse:</bold> N&#227;o h&#225; conflito com o presente artigo</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2024</year></pub-date><volume>121</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">476871</issue-id><elocation-id>e20240202</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>04</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>12</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-17 14:25:13.860"><day>17</day><month>12</month><year>2024</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="0066-782X-abc-121-11-e20240202.pdf"/><abstract abstract-type="graphical"><p>
<fig position="float" id="f01001" orientation="portrait"><label>Central Illustration:</label><caption><title>Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0066-782X-abc-121-11-e20240202-gf01-en.jpg"/></fig>
</p></abstract><abstract><title>Resumo</title><sec><title>Fundamento</title><p> A Terapia Antiplaquet&#225;ria Dupla (DAPT, do ingl&#234;s <italic toggle="yes">dual antiplatelet therapy</italic>) &#233; o tratamento de escolha para pacientes com s&#237;ndromes coronarianas agudas e cr&#244;nicas, uma vez que ela reduz mortalidade e previne complica&#231;&#245;es tromb&#243;ticas recorrentes. A avalia&#231;&#227;o da carga isqu&#234;mica e do risco de sangramento &#233; crucial na escolha da DAPT e de sua dura&#231;&#227;o.</p></sec><sec><title>Objetivos</title><p> O objetivo de nosso estudo foi conduzir um acompanhamento cl&#237;nico prospectivo de pacientes recebendo terapia combinada (AAS 75mg + clopidogrel 75 mg). Nosso estudo &#233; um estudo multic&#234;ntrico, transversal, observacional, do tipo coorte.</p></sec><sec><title>M&#233;todos</title><p> Foram inclu&#237;dos 1500 pacientes que iniciaram DAPT combinada para o tratamento de s&#237;ndrome coronariana aguda ou s&#237;ndrome coronariana cr&#244;nica. Os desfechos prim&#225;rios foram interna&#231;&#227;o hospitalar por qualquer motivo, interna&#231;&#227;o por causa cardiovascular, infarto agudo do mioc&#225;rdio, trombose de <italic toggle="yes">stent</italic>, revasculariza&#231;&#227;o de vaso alvo e sangramento; os desfechos secund&#225;rios foram morte por qualquer raz&#227;o ou por causa cardiovascular e acidente vascular cerebral. O n&#237;vel de signific&#226;ncia adotado na an&#225;lise estat&#237;stica foi 5%.</p></sec><sec><title>Resultados</title><p> A idade mediana foi 63 anos; 78,5% dos pacientes estavam recebendo DAPT por s&#237;ndrome coronariana aguda. As taxas de interna&#231;&#227;o por causas cardiovasculares, de infarto agudo do mioc&#225;rdio, de trombose de <italic toggle="yes">stent</italic> e de revasculariza&#231;&#227;o de vaso alvo foram 7,9%, 2,3%, 1,3% e 4,2%, respectivamente. Enquanto a taxa de sangramento segundo a escala BARC tipo 1 foi de 3,3%, a taxa de sangramento BARC tipo 5, 3, ou 2 foi 0,6%. As taxas dos desfechos secund&#225;rios morte por qualquer raz&#227;o, morte por causa cardiovascular e acidente vascular cerebral foram 0,5%, 0,3% e 0,3%, respectivamente.</p></sec><sec><title>Conclus&#227;o</title><p> Nosso estudo mostrou que a DAPT em regime combinado de doses fixas de AAS e clopidogrel &#233; eficaz e seguro em pacientes com s&#237;ndrome coronariana aguda ou cr&#244;nica adequadamente selecionados.</p></sec></abstract><kwd-group><kwd>Terapia Antiplaquet&#225;ria Dupla</kwd><kwd>Hemorragia</kwd><kwd>Trombose</kwd></kwd-group><counts><fig-count count="2"/><table-count count="6"/><equation-count count="0"/><ref-count count="23"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introdu&#231;&#227;o</title><p>A doen&#231;a isqu&#234;mica card&#237;aca &#233; reconhecida como a causa mais comum de mortalidade em todo o mundo, e seu tratamento vem se tornado mais e mais importante dada &#224; crescente incid&#234;ncia da doen&#231;a. A Terapia Antiplaquet&#225;ria Dupla (DAPT, do ingl&#234;s <italic toggle="yes">dual antiplatelet therapy</italic>), que consiste em inibidores de P2Y12 (ticagrelor, prasugrel ou clopidogrel), combinados com &#225;cido acetilsalic&#237;lico (AAS) &#233; recomendada para reduzir mortalidade e mesmo prevenir complica&#231;&#245;es tromb&#243;ticas recorrentes ap&#243;s eventos &#237;ndices em pacientes submetidos &#224; interven&#231;&#227;o coron&#225;ria percut&#226;nea (ICP) para s&#237;ndromes coronarianas cr&#244;nicas (SCC), em pacientes submetidos &#224; ICP por infarto do mioc&#225;rdio (IM) com Eleva&#231;&#227;o do Segmento ST (IAMSST) e por S&#237;ndrome Coronariana Aguda (SCA) sem supradesnivelamento do segmento ST (SCA-SSST), ou em pacientes tratados clinicamente.<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></sup>Nas diretrizes da ESC de 2017 para o manejo de pacientes com infarto agudo do mioc&#225;rdio com eleva&#231;&#227;o do segmento ST,<sup><xref rid="B3" ref-type="bibr">3</xref></sup> DAPT com ticagrelor ou prasugrel (ou clopidogrel 75 mg/dia de dose de manuten&#231;&#227;o se o ticagrelor ou o prasugrel n&#227;o estiver dispon&#237;vel ou for contraindicado) por 12 meses ap&#243;s a ICP em pacientes com baixo risco de sangramento em combina&#231;&#227;o com AAS 75-100mg/dia &#233; uma recomenda&#231;&#227;o classe 1, e DAPT por seis meses &#233; recomendada com uma recomenda&#231;&#227;o classe 2a em pacientes com um alto risco de sangramento.<sup><xref rid="B3" ref-type="bibr">3</xref></sup>Nas diretrizes de ESC de 2020 para o manejo de SCA sem eleva&#231;&#227;o persistente do segmento ST,<sup><xref rid="B4" ref-type="bibr">4</xref></sup> DAPT com ticagrelor ou prasugrel (ou clopidogrel 75 mg/dia de dose de manuten&#231;&#227;o se o ticagrelor ou o prasugrel n&#227;o estiver dispon&#237;vel ou for contraindicado) mais AAS 75-100mg por 12 meses em pacientes submetidos &#224; ICP e sem risco elevado de sangramento &#233; recomendada com uma indica&#231;&#227;o classe 1. DAPT com ticagrelor ou clopidogrel 75 mg/dia de dose de manuten&#231;&#227;o &#233; recomendada a pacientes acompanhados por tratamento cl&#237;nico por qualquer raz&#227;o e que n&#227;o estejam em risco de sangramento excessivo.<sup><xref rid="B4" ref-type="bibr">4</xref></sup>Nas diretrizes da ESC de 2019 para o manejo de SCC, AAS 75-100 mg/dia com clopidogrel 75 mg/day por seis meses com indica&#231;&#227;o classe 1 &#233; recomendado para pacientes submetidos &#224; ICP ap&#243;s estrat&#233;gia invasiva, independentemente do tipo de <italic toggle="yes">stent</italic>, em pacientes com alto risco de sangramento.<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p><p>A decis&#227;o sobre qual estrat&#233;gia escolher na DAPT e a dura&#231;&#227;o do tratamento baseia-se na avalia&#231;&#227;o da carga isqu&#234;mica e o risco de sangramento.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Em pacientes tratados com AAS e clopidogrel em uma dose de 75 mg separadamente ou em dose fixa combinada, a combina&#231;&#227;o de doses fixas mostrou aumentar significativamente a ades&#227;o &#224; medica&#231;&#227;o, embora nenhuma informa&#231;&#227;o sobre efic&#225;cia ou seguran&#231;a no seguimento foi apresentada.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Assim, nosso objetivo &#233; avaliar a seguran&#231;a e a efic&#225;cia de uma terapia combinada de AAS (75 mg/dia) e clopidogrel (75 mg/dia) para doen&#231;a arterial coronariana em um estudo prospectivo, observacional, multic&#234;ntrico.</p><sec sec-type="methods"><title>M&#233;todos</title><p>O DAPT-TR &#233; um estudo nacional, multic&#234;ntrico, prospectivo, observacional, do tipo coorte, conduzido em 37 universidades e dois hospitais privados em 27 cidades na Turquia. O protocolo do estudo foi revisado pelo comit&#234; de &#233;tica do Hospital Istambul de treinamento e pesquisa, e aprovado em 10 de dezembro de 2021. De acordo com diretrizes locais e resultados de ensaios cl&#237;nicos, 1500 pacientes que preencheram os crit&#233;rios de inclus&#227;o e exclus&#227;o, que iniciaram o tratamento com DAPT combinada para doen&#231;a arterial coronariana entre janeiro e dezembro de 2022, prescrito por um cardiologista, e estavam em tratamento por pelo menos um m&#234;s foram inclu&#237;dos no estudo. Todos os pacientes com SCA receberam uma carga de 300mg de AAS combinado a 600mg de clopidogrel e pacientes com SCC receberam 300mg de clopidogrel e nenhum outro agente antiplaquet&#225;rio. Todos os pacientes receberam uma combina&#231;&#227;o de DAPT em doses fixas como terapia de manuten&#231;&#227;o.</p><p>Crit&#233;rios de inclus&#227;o:</p><list list-type="bullet"><list-item><p>18-90 anos de idade, de ambos os g&#234;neros</p></list-item><list-item><p>Indica&#231;&#227;o para DAPT por SCA e/ou doen&#231;a arterial coronariana submetidos a tratamento intervencionista</p></list-item><list-item><p>Pacientes em DAPT com dose fixa combinada h&#225; pelo menos um m&#234;s.</p></list-item></list><p>Crit&#233;rios de exclus&#227;o</p><list list-type="bullet"><list-item><p>Pacientes que n&#227;o assinaram o termo de consentimento</p></list-item><list-item><p>Pacientes sem indica&#231;&#227;o para DAPT por mais de um m&#234;s ou que n&#227;o conseguiriam continuar o tratamento</p></list-item><list-item><p>Cirurgia cardiovascular ou n&#227;o-card&#237;aca planejada</p></list-item><list-item><p>Doen&#231;a hep&#225;tica grave ou doen&#231;a renal terminal</p></list-item><list-item><p>Gestantes e lactantes</p></list-item><list-item><p>Pacientes com uma expectativa de vida de menos de um ano</p></list-item><list-item><p>Pacientes em tratamento para c&#226;ncer</p></list-item><list-item><p>Trombocitopenia persistente</p></list-item><list-item><p>Pacientes em tratamento para anemia</p></list-item><list-item><p>Pacientes com &#250;lcera gastrointestinal</p></list-item><list-item><p>Pacientes sabidamente resistentes &#224; terapia antiplaquet&#225;ria</p></list-item></list><p>Caracter&#237;sticas basais, comorbidades, indica&#231;&#245;es para DAPT, medicamentos atuais, fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda no ecocardiograma, escores DAPT e PRECISE-DAPT foram registrados no momento da inclus&#227;o. Ao final do seguimento de cinco meses, os desfechos prim&#225;rios combinados &#8211; interna&#231;&#227;o por qualquer motivo, interna&#231;&#227;o por causa cardiovascular, infarto agudo do mioc&#225;rdio, trombose do <italic toggle="yes">stent</italic>, revasculariza&#231;&#227;o do vaso alvo (RVA) e sangramento &#8211; e desfechos secund&#225;rios &#8211; morte por qualquer raz&#227;o, morte por causa cardiovascular e acidente vascular cerebral &#8211; foram registrados. Interna&#231;&#245;es por causas cardiovasculares s&#227;o definidas como insufici&#234;ncia card&#237;aca, infarto agudo do mioc&#225;rdio, trombose de <italic toggle="yes">stent</italic> e arritmias como fibrila&#231;&#227;o atrial ou taquicardia ventricular. Os crit&#233;rios da Quarta Defini&#231;&#227;o Universal do IM incluem um biomarcador card&#237;aco positivo e evid&#234;ncia cl&#237;nica positiva, tais como sintomas de isquemia, altera&#231;&#245;es isqu&#234;micas no eletrocardiograma, desenvolvimento de ondas Q patol&#243;gicas e visualiza&#231;&#227;o de uma nova perda de mioc&#225;rdio vi&#225;vel ou de anormalidade da motilidade da parede em uma regi&#227;o do mioc&#225;rdio.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Trombose de <italic toggle="yes">stent</italic> foi inclu&#237;da nas diretrizes da <italic toggle="yes">Academic Research Consortium</italic> (ARC) sobre classifica&#231;&#245;es de trombose de <italic toggle="yes">stent</italic> como eventos definitivos ou confirmados (sintomas sugestivos de SCA e confirma&#231;&#227;o angiogr&#225;ficas ou patol&#243;gica de trombose de stent).<sup><xref rid="B8" ref-type="bibr">8</xref></sup> A RVA foi definida como uma interven&#231;&#227;o em qualquer art&#233;ria coron&#225;ria tratada ou n&#227;o tratada durante a ICP &#237;ndice. Sangramento foi definido segundo os crit&#233;rios do <italic toggle="yes">Bleeding Academic Research Consortium</italic> (BARC).<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p></sec><sec><title>An&#225;lise estat&#237;stica</title><p>As an&#225;lises estat&#237;sticas foram conduzidas com o SPSS vers&#227;o 21. As vari&#225;veis cont&#237;nuas foram apresentadas em mediana e intervalo interquartil por n&#227;o apresentarem distribui&#231;&#227;o normal. As vari&#225;veis categ&#243;ricas foram expressas em frequ&#234;ncias absolutas (n) e relativas (%). O teste de Kolmogorov-Smirnov foi usado para analisar normalidade da distribui&#231;&#227;o dos dados. O teste do qui-quadrado foi usado para comparar as vari&#225;veis categ&#243;ricas entre os grupos. As vari&#225;veis cont&#237;nuas sem distribui&#231;&#227;o normal foram comparadas pelo teste de Kruskal-Wallis. O teste post-hoc n&#227;o foi utilizado por n&#227;o exercer efeito sobre os desfechos cl&#237;nicos, que foram o objetivo deste estudo. Um valor de p&lt;0,05 foi considerado estatisticamente significativo, com um intervalo de confian&#231;a de 95%.</p></sec></sec><sec sec-type="results"><title>Resultados</title><p>Foram inclu&#237;dos 1500 pacientes que iniciaram DAPT combinada com doses fixas de medicamentos entre janeiro de 2022 e dezembro de 2022. Caracter&#237;sticas demogr&#225;ficas, comorbidades e indica&#231;&#245;es para DAPT da popula&#231;&#227;o do estudo s&#227;o descritas na <xref rid="t1" ref-type="table">Tabela 1</xref>. A idade mediana foi 63 (56-71) anos e 1006 (67,1%) pacientes eram do sexo masculino; 78,5% dos pacientes recebiam DAPT para SCA (26,3% IAMSST e 52,2% SCA-SSST). Idade, hipertens&#227;o, hiperlipidemia, hist&#243;ria de tabagismo, CABG pr&#233;via e hist&#243;ria de COVID foram estatisticamente diferentes entre os grupos. Valores medianos do escore PRECISE-DAPT foi 15 (8 &#8211; 23) e do escore DAPT foi 2 (1 &#8211; 3). Embora n&#227;o tenha sido observada diferen&#231;a significativa no escore PRECISE-DAPT entre os grupos, observou-se uma diferen&#231;a significativa no escore DAPT. Os tratamentos medicamentosos concomitantes s&#227;o listados na <xref rid="t2" ref-type="table">Tabela 2</xref>. A ocorr&#234;ncia de fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda inferior a 40% foi significativamente maior nos pacientes com IAMSST, assim como foi a utiliza&#231;&#227;o de ivabradina e antagonistas de mineralocorticoide nesse grupo. Os desfechos prim&#225;rios e secund&#225;rios ap&#243;s seis meses de tratamento s&#227;o apresentados na <xref rid="t3" ref-type="table">Tabela 3</xref>. Apesar das diferen&#231;as nas porcentagens nos desfechos prim&#225;rios e secund&#225;rios, n&#227;o foram observadas diferen&#231;as estatisticamente significativas entre os grupos. Os desfechos prim&#225;rios interna&#231;&#227;o hospitalar por causas cardiovasculares, infarto agudo do mioc&#225;rdio, trombose de <italic toggle="yes">stent</italic>, e RVA ocorreram em 7,9%, 2,3%, 1,3% e 4,2% dos pacientes, respectivamente. Sangramento tipo 5, 3, ou 2 (BARC) ocorreu em 3,3% dos pacientes, e BARC tipo 5, 3 ou 2 ocorreu em 0,6% dos pacientes. Os desfechos mortalidade por qualquer causa, mortalidade cardiovascular e acidente vascular cerebral ocorreram 0,5%, 0,3% e 0,3%, respectivamente (<xref rid="f01" ref-type="fig">Figura Central</xref>).</p><p>
<table-wrap position="float" id="t1" orientation="portrait"><label>Tabela 1</label><caption><title>&#8211; Caracter&#237;sticas demogr&#225;ficas, comorbidades e indica&#231;&#245;es de Terapia Antiplaquet&#225;ria Dupla (DAPT) na popula&#231;&#227;o estudada</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">Total n=1500</th><th rowspan="1" colspan="1">IAMSST n=395</th><th rowspan="1" colspan="1">SCA-SSST n=783</th><th rowspan="1" colspan="1">SCA n=322</th><th rowspan="1" colspan="1">Valor p </th></tr></thead><tbody><tr><td rowspan="3" colspan="1">Indica&#231;&#227;o de DAPT, n (%)</td><td align="center" rowspan="1" colspan="1">IAMSST</td><td align="center" rowspan="1" colspan="1">395 (26,3%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td align="center" rowspan="1" colspan="1">SCA-SSST</td><td align="center" rowspan="1" colspan="1">783 (52,2%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td align="center" rowspan="1" colspan="1">SCA</td><td align="center" rowspan="1" colspan="1">322 (21,5%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Idade, anos</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">63 (56 &#8211; 71)</td><td align="center" rowspan="1" colspan="1">62 (54 &#8211; 71)</td><td align="center" rowspan="1" colspan="1">64 (56 &#8211; 72)</td><td align="center" rowspan="1" colspan="1">62 (56 &#8211; 69)</td><td align="center" rowspan="1" colspan="1">0,013</td></tr><tr><td rowspan="1" colspan="1">Sexo masculino, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1006 (67,1%)</td><td align="center" rowspan="1" colspan="1">277 (70,1%)</td><td align="center" rowspan="1" colspan="1">527 (67,3%)</td><td align="center" rowspan="1" colspan="1">202 (62,7%)</td><td align="center" rowspan="1" colspan="1">0,109</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">543 (36,2%)</td><td align="center" rowspan="1" colspan="1">136 (34,4%)</td><td align="center" rowspan="1" colspan="1">277 (35,4%)</td><td align="center" rowspan="1" colspan="1">130 (40,4%)</td><td align="center" rowspan="1" colspan="1">0,203</td></tr><tr><td rowspan="1" colspan="1">Hipertens&#227;o, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">948 (63,2%)</td><td align="center" rowspan="1" colspan="1">226 (57,2%)</td><td align="center" rowspan="1" colspan="1">492 (62,8%)</td><td align="center" rowspan="1" colspan="1">230 (71,4%)</td><td align="center" rowspan="1" colspan="1">&lt;0,001</td></tr><tr><td rowspan="1" colspan="1">Hist&#243;ria familiar de DAC, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">568 (37,9%)</td><td align="center" rowspan="1" colspan="1">151 (38,2%)</td><td align="center" rowspan="1" colspan="1">273 (34,9%)</td><td align="center" rowspan="1" colspan="1">144 (44,7%)</td><td align="center" rowspan="1" colspan="1">0,009</td></tr><tr><td rowspan="1" colspan="1">Hiperlipidemia, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">831 (55,4%)</td><td align="center" rowspan="1" colspan="1">208 (52,7%)</td><td align="center" rowspan="1" colspan="1">423 (54%)</td><td align="center" rowspan="1" colspan="1">200 (62,1%)</td><td align="center" rowspan="1" colspan="1">0,022</td></tr><tr><td rowspan="1" colspan="1">CABG pr&#233;vio, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">130 (8,7%)</td><td align="center" rowspan="1" colspan="1">19 (4,8%)</td><td align="center" rowspan="1" colspan="1">85 (10,9%)</td><td align="center" rowspan="1" colspan="1">26 (8,1%)</td><td align="center" rowspan="1" colspan="1">0,002</td></tr><tr><td rowspan="1" colspan="1">Doen&#231;a arterial perif&#233;rica, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">114 (7,6%)</td><td align="center" rowspan="1" colspan="1">26 (6,6%)</td><td align="center" rowspan="1" colspan="1">58 (7,4%)</td><td align="center" rowspan="1" colspan="1">30 (9,3%)</td><td align="center" rowspan="1" colspan="1">0,383</td></tr><tr><td rowspan="1" colspan="1">Hist&#243;ria de sangramento, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">66 (4,4%)</td><td align="center" rowspan="1" colspan="1">12 (3%)</td><td align="center" rowspan="1" colspan="1">37 (4,7%)</td><td align="center" rowspan="1" colspan="1">17 (5,3%)</td><td align="center" rowspan="1" colspan="1">0,260</td></tr><tr><td rowspan="1" colspan="1">DPOC, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">165 (11,0%)</td><td align="center" rowspan="1" colspan="1">54 (13,7%)</td><td align="center" rowspan="1" colspan="1">80 (10,2%)</td><td align="center" rowspan="1" colspan="1">31 (9,6%)</td><td align="center" rowspan="1" colspan="1">0,136</td></tr><tr><td rowspan="1" colspan="1">Hist&#243;ria de AVC/TIA, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">60 (4,0%)</td><td align="center" rowspan="1" colspan="1">18 (4,6%)</td><td align="center" rowspan="1" colspan="1">35 (4,5%)</td><td align="center" rowspan="1" colspan="1">7 (2,2%)</td><td align="center" rowspan="1" colspan="1">0,130</td></tr><tr><td rowspan="1" colspan="1">IMC &#8805; 30kg/m<sup>2</sup>, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">301 (20,1%)</td><td align="center" rowspan="1" colspan="1">75 (19%)</td><td align="center" rowspan="1" colspan="1">165 (21,1%)</td><td align="center" rowspan="1" colspan="1">61 (18,9%)</td><td align="center" rowspan="1" colspan="1">0,596</td></tr><tr><td rowspan="3" colspan="1">Hist&#243;ria de tabagismo, n (%)</td><td align="center" rowspan="1" colspan="1">N&#227;o tabagista</td><td align="center" rowspan="1" colspan="1">619 (41,3%)</td><td align="center" rowspan="1" colspan="1">135 (34,2%)</td><td align="center" rowspan="1" colspan="1">331 (42,3%)</td><td align="center" rowspan="1" colspan="1">153 (47,5%)</td><td align="center" rowspan="3" colspan="1">&lt;0,001</td></tr><tr><td align="center" rowspan="1" colspan="1">Ex-tabagista</td><td align="center" rowspan="1" colspan="1">568 (37,9%)</td><td align="center" rowspan="1" colspan="1">152 (38,5%)</td><td align="center" rowspan="1" colspan="1">309 (39,5%)</td><td align="center" rowspan="1" colspan="1">107 (33,2%)</td></tr><tr><td align="center" rowspan="1" colspan="1">Tabagista atual</td><td align="center" rowspan="1" colspan="1">313 (20,9%)</td><td align="center" rowspan="1" colspan="1">108 (27,3%)</td><td align="center" rowspan="1" colspan="1">143 (18,3%)</td><td align="center" rowspan="1" colspan="1">62 (19,3%)</td></tr><tr><td rowspan="1" colspan="1">Consumo de &#225;lcool, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">167 (11,1%)</td><td align="center" rowspan="1" colspan="1">46 (11,6%)</td><td align="center" rowspan="1" colspan="1">97 (12,4%)</td><td align="center" rowspan="1" colspan="1">24 (7,4%)</td><td align="center" rowspan="1" colspan="1">0,056</td></tr><tr><td rowspan="1" colspan="1">Hist&#243;ria de COVID-19, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">608 (40,5%)</td><td align="center" rowspan="1" colspan="1">160 (40,5%)</td><td align="center" rowspan="1" colspan="1">343 (43,8%)</td><td align="center" rowspan="1" colspan="1">105 (32,6%)</td><td align="center" rowspan="1" colspan="1">0,003</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Vari&#225;veis categ&#243;ricas (%) e vari&#225;veis cont&#237;nuas apresentadas como mediana e intervalo interquartil; DAPT: terapia antiplaquet&#225;ria dupla; DAC: doen&#231;a arterial coronariana; CABG: bypass da art&#233;ria coron&#225;ria; DPOC: doen&#231;a pulmonar obstrutiva cr&#244;nica; AIT: acidente isqu&#234;mico transit&#243;rio; COVID-19: coronavirus disease 2019; IMC: &#237;ndice de massa corporal; IAMSST: infarto do mioc&#225;rdio (IM) com eleva&#231;&#227;o do segmento ST; SCA: s&#237;ndrome coronariana aguda; SCA-SSST: s&#237;ndrome coronariana aguda sem supradesnivelamento do Segmento ST; AVC: acidente vascular cerebral.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap position="float" id="t2" orientation="portrait"><label>Tabela 2</label><caption><title>&#8211; Caracter&#237;sticas cl&#237;nicas e tratamentos medicamentosos concomitantes dos pacientes estudados</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">Total n=1500</th><th rowspan="1" colspan="1">IAMSST n=395</th><th rowspan="1" colspan="1">SCA-SSST n=783</th><th rowspan="1" colspan="1">SCA n=322</th><th rowspan="1" colspan="1">Valor p </th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Press&#227;o arterial sist&#243;lica, mm Hg</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">130 (120 &#8211; 142)</td><td align="center" rowspan="1" colspan="1">130 (119 &#8211; 140)</td><td align="center" rowspan="1" colspan="1">130 (120 &#8211; 145)</td><td align="center" rowspan="1" colspan="1">130 (119 &#8211; 140)</td><td align="center" rowspan="1" colspan="1">0,003</td></tr><tr><td rowspan="1" colspan="1">Press&#227;o arterial diast&#243;lica, mm Hg</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">80 (70 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">78 (70 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">80 (71 &#8211; 88)</td><td align="center" rowspan="1" colspan="1">78 (70 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">&lt;0,001</td></tr><tr><td rowspan="1" colspan="1">Frequ&#234;ncia card&#237;aca, pulso/min</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">75 (68 &#8211; 84)</td><td align="center" rowspan="1" colspan="1">75 (68 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">77 (69 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">74 (66 &#8211; 81)</td><td align="center" rowspan="1" colspan="1">0,001</td></tr><tr><td rowspan="1" colspan="1">Escore PRECISE-DAPT</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">15 (8 &#8211; 23)</td><td align="center" rowspan="1" colspan="1">13 (7 &#8211; 22)</td><td align="center" rowspan="1" colspan="1">15 (8 &#8211; 24)</td><td align="center" rowspan="1" colspan="1">15 (8 &#8211; 24)</td><td align="center" rowspan="1" colspan="1">0,128</td></tr><tr><td rowspan="1" colspan="1">Escore DAPT</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">&lt;0,001</td></tr><tr><td rowspan="1" colspan="1">Hemoglobina, g/dL</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">13,7 (12,2 &#8211; 14,9)</td><td align="center" rowspan="1" colspan="1">14,0 (12,6 &#8211; 15,0)</td><td align="center" rowspan="1" colspan="1">13,6 (12,1 &#8211; 14,8)</td><td align="center" rowspan="1" colspan="1">13,6 (12,0 &#8211; 14,6)</td><td align="center" rowspan="1" colspan="1">0,005</td></tr><tr><td rowspan="1" colspan="1">LDL-colesterol, mg/dL</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">110 (85 &#8211; 137)</td><td align="center" rowspan="1" colspan="1">113 (89 &#8211; 138)</td><td align="center" rowspan="1" colspan="1">111 (86 &#8211; 138)</td><td align="center" rowspan="1" colspan="1">106 (77 &#8211; 135)</td><td align="center" rowspan="1" colspan="1">0,030</td></tr><tr><td rowspan="3" colspan="1">Fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda, n (%)</td><td align="center" rowspan="1" colspan="1">&lt;%40</td><td align="center" rowspan="1" colspan="1">152 (10,1%)</td><td align="center" rowspan="1" colspan="1">53 (13,4%)</td><td align="center" rowspan="1" colspan="1">82 (10,5%)</td><td align="center" rowspan="1" colspan="1">17 (5,3%)</td><td align="center" rowspan="3" colspan="1">&lt;0,001</td></tr><tr><td align="center" rowspan="1" colspan="1">%40-49</td><td align="center" rowspan="1" colspan="1">340 (22,7%)</td><td align="center" rowspan="1" colspan="1">120 (30,4%)</td><td align="center" rowspan="1" colspan="1">162 (20,7%)</td><td align="center" rowspan="1" colspan="1">58 (18%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8805;%50</td><td align="center" rowspan="1" colspan="1">1008 (67,2%)</td><td align="center" rowspan="1" colspan="1">222 (56,2%)</td><td align="center" rowspan="1" colspan="1">539 (68,8%)</td><td align="center" rowspan="1" colspan="1">247 (76,7%)</td></tr><tr><td rowspan="1" colspan="1">DCEI, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">24 (1,6%)</td><td align="center" rowspan="1" colspan="1">3 (0,8%)</td><td align="center" rowspan="1" colspan="1">19 (2,4%)</td><td align="center" rowspan="1" colspan="1">2 (0,6%)</td><td align="center" rowspan="1" colspan="1">0,021</td></tr><tr><td rowspan="1" colspan="1"><bold>Tratamentos medicamentosos concomitantes</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Beta-bloqueador, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1310 (87,3%)</td><td align="center" rowspan="1" colspan="1">337 (85,3%)</td><td align="center" rowspan="1" colspan="1">688 (87,9%)</td><td align="center" rowspan="1" colspan="1">285 (88,5%)</td><td align="center" rowspan="1" colspan="1">0,358</td></tr><tr><td rowspan="1" colspan="1">IECA ou BRA, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1155 (77,0%)</td><td align="center" rowspan="1" colspan="1">316 (80%)</td><td align="center" rowspan="1" colspan="1">607 (77,5%)</td><td align="center" rowspan="1" colspan="1">232 (72%)</td><td align="center" rowspan="1" colspan="1">0,037</td></tr><tr><td rowspan="1" colspan="1">ARNI, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">14 (0,9%)</td><td align="center" rowspan="1" colspan="1">2 (0,5%)</td><td align="center" rowspan="1" colspan="1">11 (1,4%)</td><td align="center" rowspan="1" colspan="1">1 (0,3%)</td><td align="center" rowspan="1" colspan="1">0,135</td></tr><tr><td rowspan="1" colspan="1">Inibidores de SGLT-2, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">138 (9,2%)</td><td align="center" rowspan="1" colspan="1">42 (10,6%)</td><td align="center" rowspan="1" colspan="1">62 (7,9%)</td><td align="center" rowspan="1" colspan="1">34 (10,6%)</td><td align="center" rowspan="1" colspan="1">0,200</td></tr><tr><td rowspan="1" colspan="1">Estatinas de intensidade alta/moderada, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1244 (82,9%)</td><td align="center" rowspan="1" colspan="1">326 (82,5%)</td><td align="center" rowspan="1" colspan="1">650 (83,0%)</td><td align="center" rowspan="1" colspan="1">268 (83,2%)</td><td align="center" rowspan="1" colspan="1">0,966</td></tr><tr><td rowspan="1" colspan="1">Bloqueadores de canais de c&#225;lcio, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">169 (11,3%)</td><td align="center" rowspan="1" colspan="1">39 (9,9%)</td><td align="center" rowspan="1" colspan="1">101 (18,3%)</td><td align="center" rowspan="1" colspan="1">29 (9%)</td><td align="center" rowspan="1" colspan="1">0,105</td></tr><tr><td rowspan="1" colspan="1">Nitratos, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">245 (16,3%)</td><td align="center" rowspan="1" colspan="1">59 (14,9%)</td><td align="center" rowspan="1" colspan="1">143 (18,3%)</td><td align="center" rowspan="1" colspan="1">43 (13,4%)</td><td align="center" rowspan="1" colspan="1">0,091</td></tr><tr><td rowspan="1" colspan="1">Ranolazina, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">225 (15,0%)</td><td align="center" rowspan="1" colspan="1">51 (12,9%)</td><td align="center" rowspan="1" colspan="1">132 (16,9%)</td><td align="center" rowspan="1" colspan="1">42 (13%)</td><td align="center" rowspan="1" colspan="1">0,109</td></tr><tr><td rowspan="1" colspan="1">Trimetazidina, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">265 (17,7%)</td><td align="center" rowspan="1" colspan="1">60 (15,2%)</td><td align="center" rowspan="1" colspan="1">145 (18,5%)</td><td align="center" rowspan="1" colspan="1">60 (18,6%)</td><td align="center" rowspan="1" colspan="1">0,322</td></tr><tr><td rowspan="1" colspan="1">Ivabradina, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">40 (2,7%)</td><td align="center" rowspan="1" colspan="1">19 (4,8%)</td><td align="center" rowspan="1" colspan="1">15 (1,9%)</td><td align="center" rowspan="1" colspan="1">6 (1,9%)</td><td align="center" rowspan="1" colspan="1">0,015</td></tr><tr><td rowspan="1" colspan="1">ARMs, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">163 (10,9%)</td><td align="center" rowspan="1" colspan="1">61 (15,4%)</td><td align="center" rowspan="1" colspan="1">84 (10,7%)</td><td align="center" rowspan="1" colspan="1">18 (5,6%)</td><td align="center" rowspan="1" colspan="1">&lt;0,001</td></tr><tr><td rowspan="1" colspan="1">IBP: n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1174 (78,3%)</td><td align="center" rowspan="1" colspan="1">303 (76,7%)</td><td align="center" rowspan="1" colspan="1">607 (77,5%)</td><td align="center" rowspan="1" colspan="1">264 (82%)</td><td align="center" rowspan="1" colspan="1">0,179</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>Vari&#225;veis categ&#243;ricas (%) e vari&#225;veis cont&#237;nuas apresentadas principalmente em mediana e intervalos interquartis; LDL: lipoprote&#237;na de baixa densidade; DCEI: dispositivo card&#237;aco eletr&#244;nico implant&#225;vel; DAPT: terapia antiplaquet&#225;ria dupla; IECA: inibidores da enzima conversora de angiotensina; BRA: bloqueadores do recetor da angiotensina; ARNI: inibidor da neprilisina e do receptor de angiotensina; SGLT-2: cotransportador s&#243;dio-glicose 2; ARMs: antagonistas dos receptores de mineralocorticoides; IBP: inibidores de bomba de pr&#243;tons.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap position="float" id="t3" orientation="portrait"><label>Tabela 3</label><caption><title>&#8211; Desfechos prim&#225;rios e secund&#225;rios</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">Total n=1500</th><th rowspan="1" colspan="1">IAMSST n=395</th><th rowspan="1" colspan="1">SCA-SSST n=783</th><th rowspan="1" colspan="1">SCA n=322</th><th rowspan="1" colspan="1">Valor p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Desfechos prim&#225;rios</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Interna&#231;&#227;o hospitalar por qualquer motivo, n (%)</td><td align="center" rowspan="1" colspan="1">193 (12,9%)</td><td align="center" rowspan="1" colspan="1">53 (13,4%)</td><td align="center" rowspan="1" colspan="1">108 (13,8%)</td><td align="center" rowspan="1" colspan="1">32 (9,9%)</td><td align="center" rowspan="1" colspan="1">0,205</td></tr><tr><td rowspan="1" colspan="1">Interna&#231;&#227;o por causa cardiovascular, n (%)</td><td align="center" rowspan="1" colspan="1">118 (7,9%)</td><td align="center" rowspan="1" colspan="1">31 (7,8%)</td><td align="center" rowspan="1" colspan="1">63 (8%)</td><td align="center" rowspan="1" colspan="1">24 (7,5%)</td><td align="center" rowspan="1" colspan="1">0,946</td></tr><tr><td rowspan="1" colspan="1">Infarto agudo do mioc&#225;rdio, n (%)</td><td align="center" rowspan="1" colspan="1">34 (2,3%)</td><td align="center" rowspan="1" colspan="1">9 (2,3%)</td><td align="center" rowspan="1" colspan="1">20 (2,6%)</td><td align="center" rowspan="1" colspan="1">5 (1,6%)</td><td align="center" rowspan="1" colspan="1">0,573</td></tr><tr><td rowspan="1" colspan="1">Trombose de <italic toggle="yes">stent</italic>, n (%)</td><td align="center" rowspan="1" colspan="1">20 (1,3%)</td><td align="center" rowspan="1" colspan="1">9 (2,3%)</td><td align="center" rowspan="1" colspan="1">9 (1,2%)</td><td align="center" rowspan="1" colspan="1">2 (0,6%)</td><td align="center" rowspan="1" colspan="1">0,127</td></tr><tr><td rowspan="1" colspan="1">Revasculariza&#231;&#227;o de vaso alvo, n (%)</td><td align="center" rowspan="1" colspan="1">63 (4,2%)</td><td align="center" rowspan="1" colspan="1">21 (5,3%)</td><td align="center" rowspan="1" colspan="1">34 (4,3%)</td><td align="center" rowspan="1" colspan="1">8 (2,5%)</td><td align="center" rowspan="1" colspan="1">0,141</td></tr><tr><td rowspan="1" colspan="1">Sangramento BARC tipo 1, n (%)</td><td align="center" rowspan="1" colspan="1">50 (3,3%)</td><td align="center" rowspan="1" colspan="1">13 (3,3%)</td><td align="center" rowspan="1" colspan="1">25 (3,2%)</td><td align="center" rowspan="1" colspan="1">12 (3,7%)</td><td align="center" rowspan="1" colspan="1">0,905</td></tr><tr><td rowspan="1" colspan="1">Sangramento BARC tipo 5, 3 ou 2, n (%)</td><td align="center" rowspan="1" colspan="1">8 (0,6%)</td><td align="center" rowspan="1" colspan="1">1 (0,3%)</td><td align="center" rowspan="1" colspan="1">5 (0,6%)</td><td align="center" rowspan="1" colspan="1">2 (0,6%)</td><td align="center" rowspan="1" colspan="1">0,672</td></tr><tr><td rowspan="1" colspan="1"><bold>Desfechos secund&#225;rios</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Morte por qualquer raz&#227;o, n (%)</td><td align="center" rowspan="1" colspan="1">8 (0,5%)</td><td align="center" rowspan="1" colspan="1">3 (0,8%)</td><td align="center" rowspan="1" colspan="1">3 (0,4%)</td><td align="center" rowspan="1" colspan="1">2 (0,6%)</td><td align="center" rowspan="1" colspan="1">0,684</td></tr><tr><td rowspan="1" colspan="1">Morte por causa cardiovascular, n (%)</td><td align="center" rowspan="1" colspan="1">5 (0,3%)</td><td align="center" rowspan="1" colspan="1">2 (0,5%)</td><td align="center" rowspan="1" colspan="1">2 (0,3%)</td><td align="center" rowspan="1" colspan="1">1 (0,3%)</td><td align="center" rowspan="1" colspan="1">0,777</td></tr><tr><td rowspan="1" colspan="1">Acidente vascular cerebral, n (%)</td><td align="center" rowspan="1" colspan="1">5 (0,3%)</td><td align="center" rowspan="1" colspan="1">2 (0,5%)</td><td align="center" rowspan="1" colspan="1">3 (0,4%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0,474</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>BARC: Bleeding Academic Research Consortium; IAMSST: infarto do mioc&#225;rdio com eleva&#231;&#227;o do segmento ST; SCA: s&#237;ndrome coronariana aguda; SCA-SSST: s&#237;ndrome coronariana aguda sem supradesnivelamento do segmento ST.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion"><title>Discuss&#227;o</title><p>Em pacientes submetidos a tratamento cl&#237;nico ou ICP por IAMSST, SCA-SSST ou SCC, as diretrizes atuais mostraram que a adi&#231;&#227;o de inibidores de P2Y12 (ticagrelor, prasugrel ou clopidogrel) ao AAS durante per&#237;odos apropriados tem efeitos favor&#225;veis sobre a mortalidade.<sup><xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B5" ref-type="bibr">5</xref></sup> A combina&#231;&#227;o da carga isqu&#234;mica com o risco de sangramento &#233; crucial na escolha do tipo e da dura&#231;&#227;o da DAPT. Idade avan&#231;ada, presen&#231;a de SCA, diabetes mellitus, doen&#231;a renal cr&#244;nica, caracter&#237;sticas angiogr&#225;ficas e escore de risco isqu&#234;mico elevado (SYNTAX 2, GRACE, TIMI, DAPT) devem ser considerados na avalia&#231;&#227;o da carga isqu&#234;mica. Na avalia&#231;&#227;o de risco de sangramento, devem ser considerados hist&#243;ria de sangramento maior, hist&#243;ria de acidente vascular cerebral, anemia, diminui&#231;&#227;o na contagem de plaquetas, doen&#231;as malignas, idade avan&#231;ada, doen&#231;a hep&#225;tica grave em uso de anticoagulantes, e elevado escore de risco de sangramento (ARC-HBR, PRECISE-DAPT). A DAPT &#233; prescrita considerando as recomenda&#231;&#245;es das diretrizes atuais, de modo a equilibrar a carga isqu&#234;mica, a qual &#233; um indicador de efic&#225;cia, e o risco de sangramento, que &#233; um indicador de seguran&#231;a. A terapia combinada com doses fixas de AAS (75mg) e clopidogrel (75mg) foi efetiva e segura em pacientes eleg&#237;veis com SCC ou aguda. No estudo CURE, que observou os efeitos da dose de AAS quando usado sozinho ou em combina&#231;&#227;o com clopidogrel em pacientes com SCA, doses mais altas de AAS (&gt;100mg) levaram a taxas mais altas de sangramento e aus&#234;ncia de efic&#225;cia adicional.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Na doen&#231;a cardiovascular ateroscler&#243;tica, dados atuais recomendam uma dose di&#225;ria de AAS entre 75 e 100mg. Na Fran&#231;a, em um estudo com 380 pacientes, AAS 75mg e clopidogrel, administrados separadamente ou de maneira combinada, melhoraram a ades&#227;o medicamentosa do paciente, mas n&#227;o foram avaliados em termos de efic&#225;cia e seguran&#231;a.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Nosso estudo &#233; o primeiro estudo prospectivo, multic&#234;ntrico, observacional a investigar a seguran&#231;a e a efic&#225;cia da combina&#231;&#227;o de doses fixas de AAS (75mg) e clopidogrel (75mg) nesses pacientes.</p><p>Em rela&#231;&#227;o aos desfechos prim&#225;rios, a taxa de interna&#231;&#227;o por causas cardiovasculares incluindo insufici&#234;ncia card&#237;aca, infarto agudo do mioc&#225;rdio, trombose de <italic toggle="yes">stent</italic> e arritmias como fibrila&#231;&#227;o atrial ou taquicardia ventricular foi de 7,9%. Cronologicamente, o uso de AAS isolado, seguido de DAPT com AAS e clopidogrel, e finalmente AAS com ticagrelor e/ou prasugrel, inibidores mais potentes do receptor para adenosina difosfato P2Y12, mostrou reduzir o risco de eventos isqu&#234;micos no mioc&#225;rdio em pacientes com SCA.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Estudos prospectivos envolvendo pacientes com SCA ou pacientes submetidos &#224; ICP em que a terapia com clopidogrel foi usada mostrou diferen&#231;as em termos de desfechos prim&#225;rios. Quando olhamos para os estudos conduzidos com pacientes com SCA, no estudo TRITON-TIMI 38,<sup><xref rid="B11" ref-type="bibr">11</xref></sup> IM foi observado em 9,7% dos pacientes no grupo recebendo clopidogrel.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> No estudo CLARITY-TIMI 28,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> a taxa de IM recorrente no bra&#231;o clopidogrel foi 2,5%,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> e no estudo CURE,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> a taxa de IM foi de 5,2% em 6,259 pacientes usando clopidogrel.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> No estudo CURRENT-OASIS 7,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> a taxa de IM foi de 2% no grupo recebendo dose dupla e 2,6% no grupo recebendo dose padr&#227;o,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> e no estudo PLATO, a taxa de IM foi 6,9% no bra&#231;o clopidogrel.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Assim, como se pode observar, apesar da taxa de IM variar entre os estudos de SCA usando clopidogrel, em nosso estudo, essa taxa foi baixa &#8211; 2,3% na popula&#231;&#227;o total, 2,3% no grupo IAMSST e 2,6% no grupo SCA-SSST. Quanto aos estudos conduzidos com paciente com SCC, no estudo EXCELLENT,<sup><xref rid="B16" ref-type="bibr">16</xref></sup> IM foi observado em 1,8% dos 722 pacientes no grupo de tratamento de seis meses de dura&#231;&#227;o.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> No estudo PRODIGY,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> a taxa de IM foi 4,2% no grupo submetido &#224; DAPT de curta dura&#231;&#227;o (seis meses), e no grupo CREDO,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> IM ocorreu em 6,6% dos pacientes no bra&#231;o clopidogrel de 1053 pacientes.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> Em uma meta-an&#225;lise de 10 ensaios controlados randomizados sobre a dura&#231;&#227;o &#243;tima da DAPT ap&#243;s ICP com <italic toggle="yes">stents</italic> farmacol&#243;gicos, a taxa de IM foi de 1,6% no tratamento de curta dura&#231;&#227;o.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> Portanto, embora a taxa de IM varie em v&#225;rios estudos usando clopidogrel, essa taxa foi baixa (como 1,6%) no subgrupo de pacientes com SCC.</p><p>Em um estudo multic&#234;ntrico, prospectivo, Oh et al.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> investigaram o potencial de inibi&#231;&#227;o plaquet&#225;ria de uma dose fixa de AAS com clopidogrel combinados e compararam com doses separadas em pacientes submetidos &#224; ICP com <italic toggle="yes">stent</italic> farmacol&#243;gico. Os autores demonstraram que a efic&#225;cia da inibi&#231;&#227;o plaquet&#225;ria terapia combinada com doses fixas das medica&#231;&#245;es n&#227;o foi diferente que a da terapia com doses separadas de AAS e clopidogrel, sem ocorr&#234;ncia de eventos cardiovasculares s&#233;rios.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> Ainda, em um estudo randomizado, Choi et al.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> mostraram que as caracter&#237;sticas farmacocin&#233;ticas da combina&#231;&#227;o de AAS e clop&#237;dogrel foram bioequivalentes a dos medicamentos administrados separadamente. Essas caracter&#237;sticas farmacocin&#233;ticas podem explicar a efic&#225;cia da terapia combinada nos desfechos cl&#237;nicos em compara&#231;&#227;o &#224; administra&#231;&#227;o das medica&#231;&#245;es de maneira isolada.<sup><xref rid="B21" ref-type="bibr">21</xref></sup></p><p>Quando olhamos para trombose de <italic toggle="yes">stent</italic>, o qual &#233; avaliado como outro indicador de efic&#225;cia, diferentes taxas t&#234;m sido relatadas entre os estudos, principalmente devido a varia&#231;&#245;es na defini&#231;&#227;o de trombose de <italic toggle="yes">stent</italic> e sele&#231;&#227;o dos pacientes. No estudo PLATO,<sup><xref rid="B15" ref-type="bibr">15</xref></sup>a trombose de <italic toggle="yes">stent</italic> ocorreu em 1,9% no bra&#231;o clopidogrel. No estudo TRITON-TIMI 38,<sup><xref rid="B11" ref-type="bibr">11</xref></sup> a taxa de trombose definitiva ou prov&#225;vel no grupo clopidogrel foi 2,4%. No ensaio CIRRENT-OASIS 7,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> observou-se uma taxa de trombose de <italic toggle="yes">stent</italic> definitiva de 0,7% no grupo recebendo dose dupla que 1,3% no grupo recebendo dose padr&#227;o.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> Embora a taxa de trombose de <italic toggle="yes">stent</italic> varie entre estudos com pacientes com SCA, em nosso estudo, ela ocorreu em 1,3% dos pacientes &#8211; 2,3% no subgrupo IAMSST e 1,3% no subgrupo SCA-SSST. Nos estudos EXCELLENT<sup><xref rid="B16" ref-type="bibr">16</xref></sup> e PRODIGY,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> trombose de <italic toggle="yes">stent</italic> definitiva e prov&#225;vel nos pacientes em DAPT por seis meses foram de 0,9% e 1,5%, respectivamente. Em uma meta-an&#225;lise de 10 estudos usando clopidogrel ap&#243;s <italic toggle="yes">stents</italic> farmacol&#243;gicos em pacientes com SCC, a taxa de trombose de <italic toggle="yes">stent</italic> foi de 0,52%.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> Em nosso estudo, a taxa de trombose de <italic toggle="yes">stent</italic> definitiva foi de 0,6% no subgrupo com SCC. Enquanto a taxa de RVA de emerg&#234;ncia foi de 3,7% no estudo TRITON-TIMI,<sup><xref rid="B11" ref-type="bibr">11</xref></sup>a taxa de revasculariza&#231;&#227;o ap&#243;s randomiza&#231;&#227;o foi de 11,5% no estudo CURE,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> a taxa de RVA foi 13,1% no estudo CREDO.<sup><xref rid="B18" ref-type="bibr">18</xref></sup>Em nosso estudo, a taxa de RVA foi de 4,2%. Tais diferen&#231;as significativas entre os estudos devem-se provavelmente a v&#225;rios fatores, incluindo estrutura do <italic toggle="yes">stent</italic>, comorbidades, e per&#237;odo de seguimento.</p><p>Quanto ao desfecho secund&#225;rio, a taxa de acidente vascular cerebral foi de 0,3% em nosso estudo. Nos estudos CHARISMA,<sup><xref rid="B22" ref-type="bibr">22</xref></sup> PLATO,<sup><xref rid="B15" ref-type="bibr">15</xref></sup> CURE<sup><xref rid="B13" ref-type="bibr">13</xref></sup> e CREDO,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> as taxas de acidente vascular cerebral foram 1,9%, 1,3%, 1,2% e 0,9%, respectivamente. Acreditamos que tais varia&#231;&#245;es devem-se &#224;s diferentes caracter&#237;sticas das popula&#231;&#245;es dos estudos.</p><p>Sangramento &#233; usado para avalia&#231;&#227;o de desfecho de seguran&#231;a das terapias antiplaquet&#225;ria, antiagregante e anticoagulante. V&#225;rias classifica&#231;&#245;es de sangramento foram estudadas, incluindo o TIMI (<italic toggle="yes">Thrombolysis in Myocardial Infarction</italic>), BARC, REPLACE-2 e GUSTO.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> No estudo CLARITY-TIMI,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> a taxa de sangramento maior segundo o escore TIMI foi de 1,9% e a de sangramento menor de 1,3% no grupo submetido &#224; ICP.<sup><xref rid="B12" ref-type="bibr">12</xref></sup> No estudo TRITON-TIMI 38, sangramento maior (TIMI) n&#227;o relacionado &#224; CABG ocorreu em 1,8% dos pacientes tratados com clopidogrel.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> No estudo CURRENT-OASIS 7,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> a taxa de sangramento maior e grave segundo defini&#231;&#227;o CURRENT foi de 2,7% no grupo que recebeu dose dupla e 1,9&#168;no grupo que recebeu dose padr&#227;o. No estudo EXCELLENT,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> a taxa de sangramento maior (escore TIMI) foi de 0,3% no grupo em DAPT de curta dura&#231;&#227;o.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> No estudo PRODIGY,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> a taxa de BARC tipo 5, 3, ou 2 foi de 3,5% e a de sangramento maior (escore TIMI) foi 0,6% no grupo em DAPT por seis meses. No estudo CREDO,<sup><xref rid="B18" ref-type="bibr">18</xref></sup>a taxa e sangramento maior (escore TIMI) n&#227;o relacionado ao procedimento foi de 1,2% no grupo de pacientes tratados com clopidogrel. Em nosso estudo, utilizamos a classifica&#231;&#227;o de BARC, e a taxa de BARC tipo 1 foi de 3,3%, de BARC tipo 5, 3 ou 2 foi de 0,6%; no subgrupo IAMSST, a taxa de BARC tipo 1 foi de 3,3%, de BARC tipo 5, 3 ou 2 foi de 0,3%; no subgrupo SCA-SSST, a taxa de BARC tipo 1 foi de 3,2%, de BARC tipo 5, 3 ou 2 foi de 0,6%; e no subgrupo SCC, a taxa de BARC tipo 1 foi de 3,7%, de BARC tipo 5, 3 ou 2 foi de 0,6%. Isso sugere que as diferen&#231;as entre os estudos podem ser atribu&#237;das aos crit&#233;rios de inclus&#227;o e de exclus&#227;o. Jung et al.<sup><xref rid="B23" ref-type="bibr">23</xref></sup> avaliaram o perfil de seguran&#231;a da terapia combinada com doses fixas de medicamentos em um ensaio randomizado. N&#227;o foram observados eventos adversos ou morte na popula&#231;&#227;o do estudo.</p><sec><title>Limita&#231;&#245;es do estudo</title><p>A primeira limita&#231;&#227;o do nosso estudo &#233; a aus&#234;ncia de estudos comparando outras DAPTs ou tratamentos com uso separado de AAS e clopidogrel. A segunda &#233; a inclus&#227;o de doen&#231;as que imp&#245;em um alto risco de sangramento nos crit&#233;rios de exclus&#227;o do paciente.</p></sec></sec><sec sec-type="conclusions"><title>Conclus&#245;es</title><p>Nosso estudo demonstra que o uso combinado de doses fixas de medicamentos na DAPT &#233; eficaz e seguro em pacientes com SCA ou SCC, selecionados conforme a carga isqu&#234;mica e o risco de sangramento.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Vincula&#231;&#227;o acad&#234;mica:</bold> N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p></fn><fn fn-type="other"><p><bold>Aprova&#231;&#227;o &#233;tica e consentimento informado:</bold> Este estudo foi aprovado pelo Comit&#234; de &#201;tica do Istanbul Training and Research Hospital sob o n&#250;mero de protocolo 2990. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#237;dos no estudo.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p><bold>Fontes de financiamento:</bold> O presente estudo n&#227;o teve fontes de financiamento externas.</p></fn></fn-group><ref-list><title>Refer&#234;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></name></person-group><article-title>Global Mortality, Disability, and the Contribution of Risk Factors: Global Burden of Disease Study</article-title><source>Lancet</source><year>1997</year><volume>349</volume><issue>9063</issue><fpage>1436</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)07495-8</pub-id><pub-id pub-id-type="pmid">9164317</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>H</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>RA</given-names></name><name name-style="western"><surname>Collet</surname><given-names>JP</given-names></name><name name-style="western"><surname>Costa</surname><given-names>F</given-names></name><name name-style="western"><surname>Jeppsson</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic Surgery (EACTS)</article-title><source>Eur Heart J</source><year>2018</year><volume>39</volume><issue>3</issue><fpage>213</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx419</pub-id><pub-id pub-id-type="pmid">28886622</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibanez</surname><given-names>B</given-names></name><name name-style="western"><surname>James</surname><given-names>S</given-names></name><name name-style="western"><surname>Agewall</surname><given-names>S</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bucciarelli-Ducci</surname><given-names>C</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2018</year><volume>39</volume><issue>2</issue><fpage>119</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id><pub-id pub-id-type="pmid">28886621</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collet</surname><given-names>JP</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>H</given-names></name><name name-style="western"><surname>Barbato</surname><given-names>E</given-names></name><name name-style="western"><surname>Barth&#233;l&#233;my</surname><given-names>O</given-names></name><name name-style="western"><surname>Bauersachs</surname><given-names>J</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><etal>et al</etal></person-group><article-title>2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>14</issue><fpage>1289</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa575</pub-id><pub-id pub-id-type="pmid">32860058</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knuuti</surname><given-names>J</given-names></name><name name-style="western"><surname>Wijns</surname><given-names>W</given-names></name><name name-style="western"><surname>Saraste</surname><given-names>A</given-names></name><name name-style="western"><surname>Capodanno</surname><given-names>D</given-names></name><name name-style="western"><surname>Barbato</surname><given-names>E</given-names></name><name name-style="western"><surname>Funck-Brentano</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>3</issue><fpage>407</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz425</pub-id><pub-id pub-id-type="pmid">31504439</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deharo</surname><given-names>P</given-names></name><name name-style="western"><surname>Quilici</surname><given-names>J</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>G</given-names></name><name name-style="western"><surname>Pankert</surname><given-names>M</given-names></name><name name-style="western"><surname>Verdier</surname><given-names>V</given-names></name><name name-style="western"><surname>Morange</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Fixed-dose Aspirin-clopidogrel Combination Enhances Compliance to Aspirin after Acute Coronary Syndrome</article-title><source>Int J Cardiol</source><year>2014</year><volume>172</volume><issue>1</issue><fpage>e1</fpage><lpage>e2</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2013.12.194</pub-id><pub-id pub-id-type="pmid">24438924</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thygesen</surname><given-names>K</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>JS</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>AS</given-names></name><name name-style="western"><surname>Chaitman</surname><given-names>BR</given-names></name><name name-style="western"><surname>Bax</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>DA</given-names></name><etal>et al</etal></person-group><article-title>Fourth Universal Definition of Myocardial Infarction (2018)</article-title><source>Eur Heart J</source><year>2019</year><volume>40</volume><issue>3</issue><fpage>237</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehy462</pub-id><pub-id pub-id-type="pmid">30165617</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutlip</surname><given-names>DE</given-names></name><name name-style="western"><surname>Windecker</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><name name-style="western"><surname>Boam</surname><given-names>A</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></name><name name-style="western"><surname>van Es</surname><given-names>GA</given-names></name><etal>et al</etal></person-group><article-title>Clinical end Points in Coronary Stent Trials: A Case for Standardized Definitions</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>17</issue><fpage>2344</fpage><lpage>2351</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.685313</pub-id><pub-id pub-id-type="pmid">17470709</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><name name-style="western"><surname>Rao</surname><given-names>SV</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>CM</given-names></name><name name-style="western"><surname>Caixeta</surname><given-names>A</given-names></name><name name-style="western"><surname>Eikelboom</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report from the Bleeding Academic Research Consortium</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>23</issue><fpage>2736</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.009449</pub-id><pub-id pub-id-type="pmid">21670242</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>SR</given-names></name><name name-style="western"><surname>Fox</surname><given-names>KA</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>BS</given-names></name><name name-style="western"><surname>Kopecky</surname><given-names>SL</given-names></name><etal>et al</etal></person-group><article-title>Effects of Aspirin Dose when Used Alone or in Combination with Clopidogrel in Patients with Acute Coronary Syndromes: Observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Study</article-title><source>Circulation</source><year>2003</year><volume>108</volume><issue>14</issue><fpage>1682</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000091201.39590.CB</pub-id><pub-id pub-id-type="pmid">14504182</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiviott</surname><given-names>SD</given-names></name><name name-style="western"><surname>Braunwald</surname><given-names>E</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>CH</given-names></name><name name-style="western"><surname>Montalescot</surname><given-names>G</given-names></name><name name-style="western"><surname>Ruzyllo</surname><given-names>W</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><issue>20</issue><fpage>2001</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0706482</pub-id><pub-id pub-id-type="pmid">17982182</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabatine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>CP</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>CM</given-names></name><name name-style="western"><surname>L&#243;pez-Send&#243;n</surname><given-names>JL</given-names></name><name name-style="western"><surname>Montalescot</surname><given-names>G</given-names></name><name name-style="western"><surname>Theroux</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-segment Elevation</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>12</issue><fpage>1179</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050522</pub-id><pub-id pub-id-type="pmid">15758000</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>SR</given-names></name><name name-style="western"><surname>Chrolavicius</surname><given-names>S</given-names></name><name name-style="western"><surname>Tognoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Fox</surname><given-names>KK</given-names></name><etal>et al</etal></person-group><article-title>Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-segment Elevation</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>7</issue><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa010746</pub-id><pub-id pub-id-type="pmid">11519503</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>SR</given-names></name><name name-style="western"><surname>Tanguay</surname><given-names>JF</given-names></name><name name-style="western"><surname>Eikelboom</surname><given-names>JW</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>SS</given-names></name><name name-style="western"><surname>Joyner</surname><given-names>CD</given-names></name><name name-style="western"><surname>Granger</surname><given-names>CB</given-names></name><etal>et al</etal></person-group><article-title>Double-dose versus Standard-dose Clopidogrel and High-dose versus Low-dose Aspirin in Individuals Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes (CURRENT-OASIS 7): A Randomised Factorial Trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9748</issue><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61088-4</pub-id><pub-id pub-id-type="pmid">20817281</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallentin</surname><given-names>L</given-names></name><name name-style="western"><surname>Becker</surname><given-names>RC</given-names></name><name name-style="western"><surname>Budaj</surname><given-names>A</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>CP</given-names></name><name name-style="western"><surname>Emanuelsson</surname><given-names>H</given-names></name><name name-style="western"><surname>Held</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>11</issue><fpage>1045</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0904327</pub-id><pub-id pub-id-type="pmid">19717846</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gwon</surname><given-names>HC</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>JY</given-names></name><name name-style="western"><surname>Park</surname><given-names>KW</given-names></name><name name-style="western"><surname>Song</surname><given-names>YB</given-names></name><name name-style="western"><surname>Chae</surname><given-names>IH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>DS</given-names></name><etal>et al</etal></person-group><article-title>Six-month versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents: The Efficacy of Xience/promus versus Cypher to Reduce Late Loss after Stenting (EXCELLENT) Randomized, Multicenter Study</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>3</issue><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.059022</pub-id><pub-id pub-id-type="pmid">22179532</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></name><name name-style="western"><surname>Campo</surname><given-names>G</given-names></name><name name-style="western"><surname>Monti</surname><given-names>M</given-names></name><name name-style="western"><surname>Vranckx</surname><given-names>P</given-names></name><name name-style="western"><surname>Percoco</surname><given-names>G</given-names></name><name name-style="western"><surname>Tumscitz</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Short- versus Long-term Duration of Dual-antiplatelet Therapy after Coronary Stenting: A Randomized Multicenter Trial</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>16</issue><fpage>2015</fpage><lpage>2026</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.071589</pub-id><pub-id pub-id-type="pmid">22438530</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinhubl</surname><given-names>SR</given-names></name><name name-style="western"><surname>Berger</surname><given-names>PB</given-names></name><name name-style="western"><surname>Mann</surname><given-names>JT</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Fry</surname><given-names>ET</given-names></name><name name-style="western"><surname>DeLago</surname><given-names>A</given-names></name><name name-style="western"><surname>Wilmer</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial</article-title><source>JAMA</source><year>2002</year><volume>288</volume><issue>19</issue><fpage>2411</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1001/jama.288.19.2411</pub-id><pub-id pub-id-type="pmid">12435254</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarese</surname><given-names>EP</given-names></name><name name-style="western"><surname>Andreotti</surname><given-names>F</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>V</given-names></name><name name-style="western"><surname>Kolodziejczak</surname><given-names>M</given-names></name><name name-style="western"><surname>Buffon</surname><given-names>A</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Optimal Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug Eluting Stents: Meta-analysis of Randomised Controlled Trials</article-title><source>BMJ</source><year>2015</year><volume>350</volume><size units="pages">h1618</size><pub-id pub-id-type="doi">10.1136/bmj.h1618</pub-id><pub-id pub-id-type="pmcid">PMC4410620</pub-id><pub-id pub-id-type="pmid">25883067</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>PC</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DW</given-names></name><name name-style="western"><surname>Hong</surname><given-names>BK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DS</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Comparative effect on Platelet Function of a Fixed-dose Aspirin and Clopidogrel Combination versus Separate Formulations in Patients with Coronary Artery Disease: A Phase IV, Multicenter, Prospective, 4-week Non-inferiority Trial</article-title><source>Int J Cardiol</source><year>2016</year><volume>202</volume><fpage>331</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.09.024</pub-id><pub-id pub-id-type="pmid">26432484</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>HK</given-names></name><name name-style="western"><surname>Ghim</surname><given-names>JL</given-names></name><name name-style="western"><surname>Shon</surname><given-names>J</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YK</given-names></name><name name-style="western"><surname>Jung</surname><given-names>JA</given-names></name></person-group><article-title>Pharmacokinetics and Relative Bioavailability of Fixed-dose Combination of Clopidogrel and Aspirin versus Coadministration of Individual Formulations in Healthy Korean Men</article-title><source>Drug Des Devel Ther</source><year>2016</year><volume>10</volume><fpage>3493</fpage><lpage>3499</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S109080</pub-id><pub-id pub-id-type="pmcid">PMC5087785</pub-id><pub-id pub-id-type="pmid">27822013</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Fox</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hacke</surname><given-names>W</given-names></name><name name-style="western"><surname>Berger</surname><given-names>PB</given-names></name><name name-style="western"><surname>Black</surname><given-names>HR</given-names></name><name name-style="western"><surname>Boden</surname><given-names>WE</given-names></name><etal>et al</etal></person-group><article-title>Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>16</issue><fpage>1706</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa060989</pub-id><pub-id pub-id-type="pmid">16531616</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Huh</surname><given-names>W</given-names></name><name name-style="western"><surname>Park</surname><given-names>KM</given-names></name><etal>et al</etal></person-group><article-title>The Pharmacokinetics and Safety of a Fixed-dose Combination of Acetylsalicylic Acid and Clopidogrel Compared with the Concurrent Administration of Acetylsalicylic Acid and Clopidogrel in Healthy Subjects: A Randomized, Open-label, 2-sequence, 2-period, Single-dose Crossover Study</article-title><source>Clin Ther</source><year>2013</year><volume>35</volume><issue>7</issue><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2013.05.015</pub-id><pub-id pub-id-type="pmid">23870608</pub-id></element-citation></ref></ref-list></back><sub-article article-type="translation" id="TRen" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20240202i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0268-9641</contrib-id><name name-style="western"><surname>&#214;z</surname><given-names initials="A">Ahmet</given-names></name><role>Conception and design of the research</role><role>Analysis and interpretation of the data</role><role>Statistical analysis and Writing of the manuscript</role><role>Acquisition of data</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8923-8709</contrib-id><name name-style="western"><surname>Toprak</surname><given-names initials="K">Kenan</given-names></name><role>Acquisition of data</role><xref rid="aff2001" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7280-5137</contrib-id><name name-style="western"><surname>Aydin</surname><given-names initials="E">Ertan</given-names></name><role>Acquisition of data</role><xref rid="aff3001" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1574-2053</contrib-id><name name-style="western"><surname>Sara&#231;</surname><given-names initials="&#x130;">&#304;brahim</given-names></name><role>Acquisition of data</role><xref rid="aff4001" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3895-1923</contrib-id><name name-style="western"><surname>Do&#287;du&#351;</surname><given-names initials="M">Mustafa</given-names></name><role>Acquisition of data</role><xref rid="aff5001" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6335-5250</contrib-id><name name-style="western"><surname>Opan</surname><given-names initials="S">Sel&#231;uk</given-names></name><role>Acquisition of data</role><xref rid="aff6001" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0933-7852</contrib-id><name name-style="western"><surname>Yener&#231;a&#287;</surname><given-names initials="M">Mustafa</given-names></name><role>Acquisition of data</role><xref rid="aff7001" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9008-6631</contrib-id><name name-style="western"><surname>Tascanov</surname><given-names initials="MB">Mustafa Begenc</given-names></name><role>Acquisition of data</role><xref rid="aff2001" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5369-5414</contrib-id><name name-style="western"><surname>K&#252;met</surname><given-names initials="&#xD6;">&#214;mer</given-names></name><role>Acquisition of data</role><xref rid="aff8001" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5688-6977</contrib-id><name name-style="western"><surname>Karaa&#287;a&#231;</surname><given-names initials="M">Mira&#231;</given-names></name><role>Acquisition of data</role><xref rid="aff9001" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6237-1398</contrib-id><name name-style="western"><surname>&#214;zmen</surname><given-names initials="M">Murat</given-names></name><role>Acquisition of data</role><xref rid="aff4001" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6564-7185</contrib-id><name name-style="western"><surname>Murat</surname><given-names initials="B">Bekta&#351;</given-names></name><role>Acquisition of data</role><xref rid="aff10001" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9951-2617</contrib-id><name name-style="western"><surname>Kertmen</surname><given-names initials="&#xD6;">&#214;mer</given-names></name><role>Acquisition of data</role><xref rid="aff11001" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0031-6457</contrib-id><name name-style="western"><surname>Bekler</surname><given-names initials="&#xD6;">&#214;zkan</given-names></name><role>Acquisition of data</role><xref rid="aff12001" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4576-128X</contrib-id><name name-style="western"><surname>&#304;nci</surname><given-names initials="S">Sinan</given-names></name><role>Acquisition of data</role><xref rid="aff13001" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8740-1429</contrib-id><name name-style="western"><surname>Huyut</surname><given-names initials="MA">Mustafa Ahmet</given-names></name><role>Acquisition of data</role><xref rid="aff14001" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4369-6146</contrib-id><name name-style="western"><surname>&#214;zderya</surname><given-names initials="A">Ahmet</given-names></name><role>Acquisition of data</role><xref rid="aff15001" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5016-5511</contrib-id><name name-style="western"><surname>Er</surname><given-names initials="F">Fahri</given-names></name><role>Acquisition of data</role><xref rid="aff16001" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5937-235X</contrib-id><name name-style="western"><surname>Duran</surname><given-names initials="M">Mustafa</given-names></name><role>Acquisition of data</role><xref rid="aff17001" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9309-803X</contrib-id><name name-style="western"><surname>Ardahanl&#305;</surname><given-names initials="&#x130;">&#304;sa</given-names></name><role>Acquisition of data</role><xref rid="aff18001" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0895-7371</contrib-id><name name-style="western"><surname>Ba&#351;</surname><given-names initials="MM">Mehmet Memduh</given-names></name><role>Acquisition of data</role><xref rid="aff19001" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8470-1928</contrib-id><name name-style="western"><surname>G&#252;zel</surname><given-names initials="T">Tuncay</given-names></name><role>Acquisition of data</role><xref rid="aff20001" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6965-5713</contrib-id><name name-style="western"><surname>Ceyhun</surname><given-names initials="G">G&#246;khan</given-names></name><role>Acquisition of data</role><xref rid="aff21001" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3953-4387</contrib-id><name name-style="western"><surname>&#214;zdemir</surname><given-names initials="&#x130;H">&#304;brahim Halil</given-names></name><role>Acquisition of data</role><xref rid="aff22001" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9499-3466</contrib-id><name name-style="western"><surname>&#214;zen</surname><given-names initials="MB">Mehmet Burak</given-names></name><role>Acquisition of data</role><xref rid="aff22001" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7133-4604</contrib-id><name name-style="western"><surname>G&#252;nd&#252;z</surname><given-names initials="R">Ramazan</given-names></name><role>Acquisition of data</role><xref rid="aff22001" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1094-5572</contrib-id><name name-style="western"><surname>Erdo&#287;an</surname><given-names initials="A">Aslan</given-names></name><role>Acquisition of data</role><xref rid="aff23001" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0331-9167</contrib-id><name name-style="western"><surname>&#199;etin</surname><given-names initials="&#x130;">&#304;lyas</given-names></name><role>Acquisition of data</role><xref rid="aff23001" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3021-8612</contrib-id><name name-style="western"><surname>Bar&#305;&#351;</surname><given-names initials="V&#xD6;">Veysel &#214;zg&#252;r</given-names></name><role>Acquisition of data</role><xref rid="aff24001" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5302-4052</contrib-id><name name-style="western"><surname>Yayla</surname><given-names initials="&#xC7;">&#199;a&#287;r&#305;</given-names></name><role>Acquisition of data</role><xref rid="aff25001" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6080-6335</contrib-id><name name-style="western"><surname>Karaduman</surname><given-names initials="M">Medeni</given-names></name><role>Acquisition of data</role><xref rid="aff26001" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7768-2562</contrib-id><name name-style="western"><surname>A&#351;k&#305;n</surname><given-names initials="L">L&#252;tf&#252;</given-names></name><role>Acquisition of data</role><xref rid="aff27001" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3920-1382</contrib-id><name name-style="western"><surname>Bekar</surname><given-names initials="L">L&#252;tf&#252;</given-names></name><role>Acquisition of data</role><xref rid="aff28001" ref-type="aff">
<sup>28</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3531-8409</contrib-id><name name-style="western"><surname>Tanr&#305;verdi</surname><given-names initials="O">Okan</given-names></name><role>Acquisition of data</role><xref rid="aff29001" ref-type="aff">
<sup>29</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0792-628X</contrib-id><name name-style="western"><surname>&#214;zkan</surname><given-names initials="E">Ey&#252;p</given-names></name><role>Acquisition of data</role><xref rid="aff23001" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4102-444X</contrib-id><name name-style="western"><surname>Ye&#351;il</surname><given-names initials="E">Emrah</given-names></name><role>Acquisition of data</role><xref rid="aff30001" ref-type="aff">
<sup>30</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0260-5463</contrib-id><name name-style="western"><surname>&#199;al&#305;&#351;kan</surname><given-names initials="S">Serhat</given-names></name><role>Acquisition of data</role><xref rid="aff31001" ref-type="aff">
<sup>31</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5378-5516</contrib-id><name name-style="western"><surname>Kuzu</surname><given-names initials="Z">Z&#252;lfiye</given-names></name><role>Acquisition of data</role><xref rid="aff32001" ref-type="aff">
<sup>32</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4834-5572</contrib-id><name name-style="western"><surname>U&#287;uz</surname><given-names initials="B">Berat</given-names></name><role>Acquisition of data</role><xref rid="aff33001" ref-type="aff">
<sup>33</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2313-1495</contrib-id><name name-style="western"><surname>B&#246;y&#252;k</surname><given-names initials="F">Ferit</given-names></name><role>Acquisition of data</role><xref rid="aff34001" ref-type="aff">
<sup>34</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8930-3651</contrib-id><name name-style="western"><surname>Kunak</surname><given-names initials="A&#xDC;">Ay&#351;eg&#252;l &#220;lgen</given-names></name><role>Acquisition of data</role><xref rid="aff35001" ref-type="aff">
<sup>35</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3935-0222</contrib-id><name name-style="western"><surname>Murat</surname><given-names initials="S">Selda</given-names></name><role>Acquisition of data</role><xref rid="aff36001" ref-type="aff">
<sup>36</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6782-4237</contrib-id><name name-style="western"><surname>Asil</surname><given-names initials="S">Serkan</given-names></name><role>Acquisition of data</role><xref rid="aff37001" ref-type="aff">
<sup>37</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0379-7812</contrib-id><name name-style="western"><surname>Kayhan</surname><given-names initials="&#xD6;">&#214;zkan</given-names></name><role>Acquisition of data</role><xref rid="aff38001" ref-type="aff">
<sup>38</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2329-6310</contrib-id><name name-style="western"><surname>Erdo&#287;an</surname><given-names initials="E">Emrah</given-names></name><role>Acquisition of data</role><xref rid="aff39001" ref-type="aff">
<sup>39</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5022-4040</contrib-id><name name-style="western"><surname>Duz</surname><given-names initials="R">Ramazan</given-names></name><role>Acquisition of data</role><xref rid="aff39001" ref-type="aff">
<sup>39</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6818-0106</contrib-id><name name-style="western"><surname>Katkat</surname><given-names initials="F">Fahrettin</given-names></name><role>Acquisition of data</role><xref rid="aff40001" ref-type="aff">
<sup>40</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4015-1711</contrib-id><name name-style="western"><surname>Ekin</surname><given-names initials="T">Tuba</given-names></name><role>Acquisition of data</role><xref rid="aff41001" ref-type="aff">
<sup>41</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1231-0933</contrib-id><name name-style="western"><surname>&#304;bi&#351;o&#287;lu</surname><given-names initials="E">Ersin</given-names></name><role>Acquisition of data</role><xref rid="aff23001" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9531-8350</contrib-id><name name-style="western"><surname>Ate&#351;</surname><given-names initials="BN">Bilge Nazar</given-names></name><role>Acquisition of data</role><xref rid="aff42001" ref-type="aff">
<sup>42</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9901-9419</contrib-id><name name-style="western"><surname>Ay&#231;a</surname><given-names initials="B">Burak</given-names></name><role>Conception and design of the research</role><role>Critical revision of the manuscript for content</role><xref rid="aff40001" ref-type="aff">
<sup>40</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1775-4063</contrib-id><name name-style="western"><surname>Ergene</surname><given-names initials="AO">As&#305;m Oktay</given-names></name><role>Conception and design of the research</role><role>Critical revision of the manuscript for content</role><xref rid="aff43001" ref-type="aff">
<sup>43</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8156-2675</contrib-id><name name-style="western"><surname>Zoghi</surname><given-names initials="M">Mehdi</given-names></name><role>Conception and design of the research</role><role>Critical revision of the manuscript for content</role><xref rid="aff44001" ref-type="aff">
<sup>44</sup>
</xref></contrib></contrib-group><aff id="aff1001">
<label>1</label>
<country country="TR">Turkey</country>
<institution content-type="original">Department of Cardiology, Health Science University, Istanbul Training and Research Hospital, Istanbul &#8211; Turkey</institution>
</aff><aff id="aff2001">
<label>2</label>
<country country="TR">Turkey</country>
<institution content-type="original">Harran University, Faculty of Medicine, Department of Cardiology, Sanliurfa &#8211; Turkey</institution>
</aff><aff id="aff3001">
<label>3</label>
<country country="TR">Turkey</country>
<institution content-type="original">Giresun Training and Research Hospital, Department of Cardiology, Giresun &#8211; Turkey</institution>
</aff><aff id="aff4001">
<label>4</label>
<country country="TR">Turkey</country>
<institution content-type="original">Erzurum City Hospital, Department of Cardiology, Erzurum &#8211; Turkey</institution>
</aff><aff id="aff5001">
<label>5</label>
<country country="TR">Turkey</country>
<institution content-type="original">U&#351;ak University Training and Research Hospital, Department of Cardiology, Usak &#8211; Turkey</institution>
</aff><aff id="aff6001">
<label>6</label>
<country country="TR">Turkey</country>
<institution content-type="original">Sanliurfa Training and Research Hospital, Department of Cardiology, &#350;anl&#305;urfa &#8211; Turkey</institution>
</aff><aff id="aff7001">
<label>7</label>
<country country="TR">Turkey</country>
<institution content-type="original">Samsun University, Faculty of Medicine, Department of Cardiology, Samsun &#8211; Turkey</institution>
</aff><aff id="aff8001">
<label>8</label>
<country country="TR">Turkey</country>
<institution content-type="original">Van Training and Research Hospital, Department of Cardiology, Van &#8211; Turkey</institution>
</aff><aff id="aff9001">
<label>9</label>
<country country="TR">Turkey</country>
<institution content-type="original">&#304;n&#246;n&#252; University Turgut &#214;zal T&#305;p Merkezi Training and Research Hospital, Department of Cardiology, Malatya &#8211; Turkey</institution>
</aff><aff id="aff10001">
<label>10</label>
<country country="TR">Turkey</country>
<institution content-type="original">Eski&#351;ehir City Hospital, Department of Cardiology, Eski&#351;ehir &#8211; Turkey</institution>
</aff><aff id="aff11001">
<label>11</label>
<country country="TR">Turkey </country>
<institution content-type="original">Amasya University Sabuncuo&#287;lu &#350;erefeddin Training and Research Hospital, Department of Cardiology, Amasya &#8211; Turkey </institution>
</aff><aff id="aff12001">
<label>12</label>
<country country="TR">Turkey</country>
<institution content-type="original">Mustafa Kemal University, Faculty of Medicine, Department of Cardiology, Hatay &#8211; Turkey</institution>
</aff><aff id="aff13001">
<label>13</label>
<country country="TR">Turkey</country>
<institution content-type="original">Aksaray University, Faculty of Medicine, Department of Cardiology, Aksaray &#8211; Turkey</institution>
</aff><aff id="aff14001">
<label>14</label>
<country country="TR">Turkey</country>
<institution content-type="original">&#304;stanbul Prof.Dr.Cemil Ta&#351;c&#305;o&#287;lu City Hospital, Department of Cardiology, &#304;stanbul &#8211; Turkey</institution>
</aff><aff id="aff15001">
<label>15 </label>
<country country="TR">Turkey</country>
<institution content-type="original">Trabzon Kanuni Training and Research Hospital, Department of Cardiology,Trabzon &#8211; Turkey</institution>
</aff><aff id="aff16001">
<label>16</label>
<country country="TR">Turkey</country>
<institution content-type="original">A&#287;r&#305; Training and Research Hospital, Department of Cardiology, A&#287;r&#305; &#8211; Turkey</institution>
</aff><aff id="aff17001">
<label>17</label>
<country country="TR">Turkey</country>
<institution content-type="original">Konya City Hospital, Department of Cardiology, Konya &#8211; Turkey</institution>
</aff><aff id="aff18001">
<label>18</label>
<country country="TR">Turkey</country>
<institution content-type="original">Bilcecik &#350;eyh Edebali University, Faculty of Medicine, Department of Cardiology, Bilecik &#8211; Turkey</institution>
</aff><aff id="aff19001">
<label>19</label>
<country country="TR">Turkey</country>
<institution content-type="original">Private Meydan Hospital, Department of Cardiology, &#350;anl&#305;urfa &#8211; Turkey</institution>
</aff><aff id="aff20001">
<label>20</label>
<country country="TR">Turkey</country>
<institution content-type="original">Gazi Ya&#351;argil Training and Research Hospital, Department of Cardiology, Diyarbak&#305;r &#8211; Turkey</institution>
</aff><aff id="aff21001">
<label>21</label>
<country country="TR">Turkey</country>
<institution content-type="original">Atat&#252;rk University, Faculty of Medicine, Department of Cardiology, Erzurum &#8211; Turkey</institution>
</aff><aff id="aff22001">
<label>22</label>
<country country="TR">Turkey</country>
<institution content-type="original">Manisa City Hospital, Department of Cardiology, Manisa &#8211; Turkey</institution>
</aff><aff id="aff23001">
<label>23</label>
<country country="TR">Turkey</country>
<institution content-type="original">Ba&#351;ak&#351;ehir &#199;am ve Sakura City Hospital, Department of Cardiology, &#304;stanbul &#8211; Turkey</institution>
</aff><aff id="aff24001">
<label>24</label>
<country country="TR">Turkey</country>
<institution content-type="original">Gaziantep Dr. Ersin Arslan Training and Research Hospital, Department of Cardiology, Gaziantep &#8211; Turkey</institution>
</aff><aff id="aff25001">
<label>25</label>
<country country="TR">Turkey</country>
<institution content-type="original">Ankara Bilkent City Hospital, Department of Cardiology, Ankara &#8211; Turkey</institution>
</aff><aff id="aff26001">
<label>26</label>
<country country="TR">Turkey </country>
<institution content-type="original">Van Y&#252;z&#252;nc&#252; Y&#305;l University, Faculty of Medicine, Department of Cardiology, Van &#8211; Turkey </institution>
</aff><aff id="aff27001">
<label>27</label>
<country country="TR">Turkey</country>
<institution content-type="original">Gaziantep &#304;slam Bilim ve Teknoloji University, Faculty of Medicine, Department of Cardiology, Gaziantep &#8211; Turkey</institution>
</aff><aff id="aff28001">
<label>28</label>
<country country="TR">Turkey</country>
<institution content-type="original">Hitit University, Faculty of Medicine, Department of Cardiology, &#199;orum &#8211; Turkey</institution>
</aff><aff id="aff29001">
<label>29</label>
<country country="TR">Turkey</country>
<institution content-type="original">Ad&#305;yaman University, Faculty of Medicine, Department of Cardiology, Ad&#305;yaman &#8211; Turkey</institution>
</aff><aff id="aff30001">
<label>30</label>
<country country="TR">Turkey </country>
<institution content-type="original">Mersin University, Faculty of Medicine, Department of Cardiology, Mersin &#8211; Turkey </institution>
</aff><aff id="aff31001">
<label>31</label>
<country country="TR">Turkey</country>
<institution content-type="original">Bah&#231;elievler State Hospital, Department of Cardiology, &#304;stanbul &#8211; Turkey</institution>
</aff><aff id="aff32001">
<label>32</label>
<country country="TR">Turkey</country>
<institution content-type="original">Kayseri City Hospital, Department of Cardiology, Kayseri &#8211; Turkey</institution>
</aff><aff id="aff33001">
<label>33</label>
<country country="TR">Turkey</country>
<institution content-type="original">Bursa City Hospital, Department of Cardiology, Bursa &#8211; Turkey</institution>
</aff><aff id="aff34001">
<label>34</label>
<country country="TR">Turkey</country>
<institution content-type="original">Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Cardiology, &#304;stanbul &#8211; Turkey</institution>
</aff><aff id="aff35001">
<label>35</label>
<country country="TR">Turkey</country>
<institution content-type="original">Band&#305;rma Training and Research Hospital, Department of Cardiology, Bal&#305;kesir &#8211; Turkey</institution>
</aff><aff id="aff36001">
<label>36</label>
<country country="TR">Turkey</country>
<institution content-type="original">Eski&#351;ehir Osmangazi University, Faculty of Medicine, Department of Cardiology, Eski&#351;ehir &#8211; Turkey</institution>
</aff><aff id="aff37001">
<label>37</label>
<country country="TR">Turkey</country>
<institution content-type="original">G&#252;lhane Training and Research Hospital, Department of Cardiology, Ankara &#8211; Turkey</institution>
</aff><aff id="aff38001">
<label>38</label>
<country country="TR">Turkey</country>
<institution content-type="original">Kepez State Hospital, Department of Cardiology, Antalya &#8211; Turkey</institution>
</aff><aff id="aff39001">
<label>39</label>
<country country="TR">Turkey</country>
<institution content-type="original">Van Y&#252;z&#252;nc&#252; Y&#305;l University, Faculty of Medicine, Department of Cardiology, Van &#8211; Turkey</institution>
</aff><aff id="aff40001">
<label>40</label>
<country country="TR">Turkey</country>
<institution content-type="original">&#304;stanbul Training and Research Hospital, Department of Cardiology, &#304;stanbul &#8211; Turkey</institution>
</aff><aff id="aff41001">
<label>41</label>
<country country="TR">Turkey</country>
<institution content-type="original">K&#305;r&#351;ehir Ahi Evran University Training and Research Hospital, Department of Cardiology, K&#305;r&#351;ehir &#8211; Turkey</institution>
</aff><aff id="aff42001">
<label>42</label>
<country country="TR">Turkey</country>
<institution content-type="original">Ankara University, Faculty of Medicine, Department of Cardiology, Ankara &#8211; Turkey</institution>
</aff><aff id="aff43001">
<label>43</label>
<country country="TR">Turkey</country>
<institution content-type="original">Dokuz Eylul University, Department of Cardiology, Izmir &#8211; Turkey</institution>
</aff><aff id="aff44001">
<label>44</label>
<country country="TR">Turkey</country>
<institution content-type="original">Ege University, Department of Cardiology, Izmir &#8211; Turkey</institution>
</aff><author-notes><corresp id="c01001"><label>Mailing Address:</label> Ahmet &#214;z &#8226; Istanbul Training and Research Hospital - &#304;stanbul Istanbul 34100 - Turkey; E-mail: drozahmet@gmail.com </corresp><fn fn-type="edited-by"><p><bold>Editor responsible for the review:</bold> Gl&#225;ucia Maria Moraes de Oliveira</p></fn><fn fn-type="COI-statement"><p><bold>Potential conflict of interest:</bold> No potential conflict of interest relevant to this article was reported.</p></fn></author-notes><abstract abstract-type="graphical"><p>
<fig position="float" id="f01" orientation="portrait"><label>Figura Central</label><caption><title>: Terapia Antiplaquet&#225;ria Dupla Combinada em Pacientes com Doen&#231;a Arterial Coronariana em uma Popula&#231;&#227;o na Turquia: DAPT-TR</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0066-782X-abc-121-11-e20240202-gf01.jpg"/></fig>
</p></abstract><abstract><title>Abstract</title><sec><title>Background</title><p> Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued.</p></sec><sec><title>Objectives</title><p> The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study.</p></sec><sec><title>Methods</title><p> A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%.</p></sec><sec><title>Results</title><p> Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.</p></sec></abstract><kwd-group><kwd>Dual Anti-Platelet Therapy</kwd><kwd>Hemorrhage</kwd><kwd>Thrombosis</kwd></kwd-group></front-stub><body><sec sec-type="intro"><title>Introduction</title><p>Ischemic heart disease is recognised as the most common cause of death worldwide and its treatment management has become more and more important due to the increasing incidence of the disease. Dual antiplatelet therapy (DAPT) consisting of P2Y12 inhibitors (ticagrelor, prasugrel or clopidogrel) combined with acetylsalicylic acid (ASA) is recommended to reduce mortality and prevent recurrent thrombotic complications after index events in patients undergoing percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS), in patients undergoing PCI for ST-elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), or in patients treated medically.<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></sup> In the 2017 ESC Guideline for Acute Myocardial Infarction (MI) in Patients Presenting with ST-Segment Elevation,<sup><xref rid="B3" ref-type="bibr">3</xref></sup> DAPT with ticagrelor or prasugrel (or clopidogrel 75 mg/day maintenance dose if ticagrelor or prasugrel is not available or contraindicated) for 12 months after PCI in patients with low bleeding risk in combination with ASA 75-100 mg/day is a class 1 recommendation, while DAPT for six months is a class 2a recommendation in patients with high bleeding risk.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> Similarly, in the 2020 ESC guidelines for ACS without persistent ST-segment elevation,<sup><xref rid="B4" ref-type="bibr">4</xref></sup> DAPT with ticagrelor or prasugrel (or clopidogrel 75 mg/day maintenance dose if ticagrelor or prasugrel is not available or contraindicated) plus ASA 75-100 mg/day for 12 months in patients undergoing PCI and not at high risk of bleeding is recommended with a class 1 indication. DAPT with ticagrelor or clopidogrel 75 mg/day maintenance dose is recommended in patients who are followed up with medical treatment for any reason and who are not at risk of excessive bleeding.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> In the 2019 ESC guidelines for chronic coronary syndromes, ASA 75-100 mg/day with clopidogrel 75 mg/day for 6 months with class 1 indication is recommended for patients undergoing PCI after invasive strategy, regardless of stent type, in patients without high bleeding risk.<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p><p>The decision on which strategy to choose in DAPT and the duration of treatment is based on the evaluation of ischaemic burden and bleeding risk.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> In patients treated with ASA and clopidogrel at a dose of 75 mg separately or in fixed-dose combination, fixed-dose combination has been shown to significantly increase drug adherence, but no information on efficacy or safety in follow-up has been provided.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Therefore, we aimed to evaluate the safety and efficacy of a fixed-dose ASA (75 mg/day) &#8211; clopidogrel (75mg/day) combination for coronary artery disease in a prospective, multicentric, observational study.</p></sec><sec sec-type="methods"><title>Methods</title><p>DAPT-TR is a national, multicentric, prospective and observational cohort study conducted in 37 universities and two private hospitals in 27 cities in Turkey. The study protocol was reviewed by the Ethics Committee of Istanbul Training and Research Hospital and approved on 10 December 2021. In accordance with current guidelines and results of clinical trials, 1500 patients who met the inclusion and exclusion criteria, who were started on fixed dose combination DAPT treatment for coronary artery disease between January 2022 and December 2022 by a cardiologist and received this drug treatment for at least 1 month, were included in the study. All patients with acute coronary syndrome were loaded with 300 mg ASA along with 600 mg clopidogrel and patients with CCS received 300 mg clopidogrel and no other antiplatelet agents were used. All patients received fixed-dose combination DAPT as maintenance therapy.</p><p>Inclusion criteria:</p><list list-type="bullet"><list-item><p>18-90 years of age, regardless of gender</p></list-item><list-item><p>Indication for DAPT due to acute coronary syndrome and/or coronary artery disease undergoing interventional treatment</p></list-item><list-item><p>Patients who have been on fixed-dose combination therapy for at least one month</p></list-item></list><p>Exclusion criteria:</p><list list-type="bullet"><list-item><p>Patients who did not sign a consent form</p></list-item><list-item><p>Those who had no indication for dual antiplatelet therapy for more than one month or who was not be able to continue treatment</p></list-item><list-item><p>Non-cardiac or cardiovascular surgery planned</p></list-item><list-item><p>Severe liver disease or end-stage renal failure</p></list-item><list-item><p>Pregnant and breastfeeding women</p></list-item><list-item><p>Patients with a life expectancy of less than one year</p></list-item><list-item><p>Those undergoing cancer treatment</p></list-item><list-item><p>Persistent thrombocytopenia</p></list-item><list-item><p>Those receiving treatment for anaemia</p></list-item><list-item><p>Known gastrointestinal ulcers</p></list-item><list-item><p>Patients known to be resistant to antiplatelet therapy</p></list-item></list><p>Baseline characteristics, comorbidities, indications for DAPT, current medication, echocardiographic left ventricular ejection fraction, DAPT and PRECISE-DAPT scores were recorded at the time of inclusion. At the end of five-month follow-up, the combined primary endpoints &#8211; hospitalization for any reason, hospitalization for cardiovascular cause, acute MI, stent thrombosis, target vessel revascularization (TVR) and bleeding] and secondary endpoints (death for any reason, death from cardiovascular cause, stroke) were recorded. Hospitalizations for cardiovascular reasons are defined as heart failure, acute MI, stent thrombosis and rhythm disorders such as atrial fibrillation or ventricular tachycardia. The criteria according to the Fourth Universal Definition of MI include a positive cardiac biomarker and corroborating clinical evidence, such as ischaemic symptoms, new ischaemic electrocardiographic changes, development of pathological Q waves and visualization of a new loss of viable myocardium or regional wall motion abnormality.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Stent thrombosis was included in the 2008 Academic Research Consortium (ARC) guidelines on stent thrombosis classifications as definite or confirmed events (symptoms suggestive of acute coronary syndrome and angiographic or pathological confirmation of stent thrombosis).<sup><xref rid="B8" ref-type="bibr">8</xref></sup> TVR was defined as an intervention in any coronary artery treated or untreated during the index PCI. Bleeding was defined according to the Bleeding Academic Research Consortium (BARC) criteria.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p><sec><title>Statistical analysis</title><p>Statistical analyses were carried out with SPSS version 21. Continuous variables were presented as median and interquartile range as they did not show normal distribution. Categorical variables were expressed as absolute (n) and relative frequencies (%). The Kolmogorov-Smirnov test was used to assess the normality of data distribution. Chi-square test was used to compare categorical variables between groups. Continuous variables without normal distribution were compared using the Kruskal-Wallis test, and post hoc test was not used because it had no effect on the clinical outcomes, which was the aim of the study. A p&lt;0.05 was considered significant with 95% confidence interval.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 1,500 patients who started fixed-dose combination therapy between January 2022 and December 2022 were included. Demographic characteristics, comorbid conditions and DAPT indications of the study population are shown in <xref rid="t1001" ref-type="table">Table 1</xref>. Median age was 63 (56 &#8211; 71) years and 1006 (67.1%) patients were male; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome (26.3% STEMI and 52.2% NSTE-ACS). Age, hypertension, hyperlipidemia, smoking history, previous CABG and COVID history were found to be statistically significant between the groups. The median PRECISE-DAPT score was 15 (8 &#8211; 23) and the median DAPT score was 2 (1 &#8211; 3). Although there was no significant difference between the groups in the PRECISE-DAPT score, a significant difference was observed in the DAPT score. The concurrent drug treatments are listed in <xref rid="t2001" ref-type="table">Table 2</xref>. Occurence of left ventricular ejection fraction &lt;40% was found to be significantly higher in the STEMI group, and accordingly, the use of ivabradine and mineralocorticoid receptor antagonists was found to be statistically higher. The primary and secondary endpoints after six months of treatment, are shown in <xref rid="t3001" ref-type="table">Table 3</xref>. Although there were percentage differences in the primary and secondary endpoints, no statistically significant difference was found between the groups. The primary endpoints consisting of hospitalization for cardiovascular reasons, acute MI, stent thrombosis and TVR were 7.9%, 2.3%, 1.3% and 4.2%, respectively. BARC type 1 bleeding occurred in 3.3% of patients, while BARC type 5, 3, or 2 bleeding occurred in 0.6%. The secondary endpoints consisting of death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively (<xref rid="f01001" ref-type="fig">Central Illustration</xref>).</p><p>
<table-wrap position="float" id="t1001" orientation="portrait"><label>Table 1</label><caption><title>&#8211; Demographic characteristics, comorbid conditions and dual antiplatelet therapy (DAPT) indications of the study population</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">Total n=1500</th><th rowspan="1" colspan="1">STEMI n=395</th><th rowspan="1" colspan="1">NSTE-ACS n=783</th><th rowspan="1" colspan="1">CCS n=322</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">DAPT indications, n (%)</td><td align="center" rowspan="1" colspan="1">STEMI</td><td align="center" rowspan="1" colspan="1">395 (26.3%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td align="center" rowspan="1" colspan="1">NSTE-ACS</td><td align="center" rowspan="1" colspan="1">783 (52.2%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td align="center" rowspan="1" colspan="1">CCS</td><td align="center" rowspan="1" colspan="1">322 (21.5%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">63 (56 &#8211; 71)</td><td align="center" rowspan="1" colspan="1">62 (54 &#8211; 71)</td><td align="center" rowspan="1" colspan="1">64 (56 &#8211; 72)</td><td align="center" rowspan="1" colspan="1">62 (56 &#8211; 69)</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td rowspan="1" colspan="1">Gender (male), n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1006 (67.1%)</td><td align="center" rowspan="1" colspan="1">277 (70.1%)</td><td align="center" rowspan="1" colspan="1">527 (67.3%)</td><td align="center" rowspan="1" colspan="1">202 (62.7%)</td><td align="center" rowspan="1" colspan="1">0.109</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">543 (36.2%)</td><td align="center" rowspan="1" colspan="1">136 (34.4%)</td><td align="center" rowspan="1" colspan="1">277 (35.4%)</td><td align="center" rowspan="1" colspan="1">130 (40.4%)</td><td align="center" rowspan="1" colspan="1">0.203</td></tr><tr><td rowspan="1" colspan="1">Hypertension, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">948 (63.2%)</td><td align="center" rowspan="1" colspan="1">226 (57.2%)</td><td align="center" rowspan="1" colspan="1">492 (62.8%)</td><td align="center" rowspan="1" colspan="1">230 (71.4%)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Family history of CAD, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">568 (37.9%)</td><td align="center" rowspan="1" colspan="1">151 (38.2%)</td><td align="center" rowspan="1" colspan="1">273 (34.9%)</td><td align="center" rowspan="1" colspan="1">144 (44.7%)</td><td align="center" rowspan="1" colspan="1">0.009</td></tr><tr><td rowspan="1" colspan="1">Hyperlipidemia, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">831 (55.4%)</td><td align="center" rowspan="1" colspan="1">208 (52.7%)</td><td align="center" rowspan="1" colspan="1">423 (54%)</td><td align="center" rowspan="1" colspan="1">200 (62.1%)</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">Prior CABG,n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">130 (8.7%)</td><td align="center" rowspan="1" colspan="1">19 (4.8%)</td><td align="center" rowspan="1" colspan="1">85 (10.9%)</td><td align="center" rowspan="1" colspan="1">26 (8.1%)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Peripheral arterial disease, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">114 (7.6%)</td><td align="center" rowspan="1" colspan="1">26 (6.6%)</td><td align="center" rowspan="1" colspan="1">58 (7.4%)</td><td align="center" rowspan="1" colspan="1">30 (9.3%)</td><td align="center" rowspan="1" colspan="1">0.383</td></tr><tr><td rowspan="1" colspan="1">Bleeding history, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">66 (4.4%)</td><td align="center" rowspan="1" colspan="1">12 (3%)</td><td align="center" rowspan="1" colspan="1">37 (4.7%)</td><td align="center" rowspan="1" colspan="1">17 (5.3%)</td><td align="center" rowspan="1" colspan="1">0.260</td></tr><tr><td rowspan="1" colspan="1">COPD, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">165 (11.0%)</td><td align="center" rowspan="1" colspan="1">54 (13.7%)</td><td align="center" rowspan="1" colspan="1">80 (10.2%)</td><td align="center" rowspan="1" colspan="1">31 (9.6%)</td><td align="center" rowspan="1" colspan="1">0.136</td></tr><tr><td rowspan="1" colspan="1">History of stroke/TIA, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">60 (4.0%)</td><td align="center" rowspan="1" colspan="1">18 (4.6%)</td><td align="center" rowspan="1" colspan="1">35 (4.5%)</td><td align="center" rowspan="1" colspan="1">7 (2.2%)</td><td align="center" rowspan="1" colspan="1">0.130</td></tr><tr><td rowspan="1" colspan="1">BMI &#8805; 30kg/m<sup>2</sup>, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">301 (20.1%)</td><td align="center" rowspan="1" colspan="1">75 (19%)</td><td align="center" rowspan="1" colspan="1">165 (21.1%)</td><td align="center" rowspan="1" colspan="1">61 (18.9%)</td><td align="center" rowspan="1" colspan="1">0.596</td></tr><tr><td rowspan="3" colspan="1">History of smoking, n (%)</td><td align="center" rowspan="1" colspan="1">Non-smoker</td><td align="center" rowspan="1" colspan="1">619 (41.3%)</td><td align="center" rowspan="1" colspan="1">135 (34.2%)</td><td align="center" rowspan="1" colspan="1">331 (42.3%)</td><td align="center" rowspan="1" colspan="1">153 (47.5%)</td><td align="center" rowspan="3" colspan="1">&lt;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Former-smoker</td><td align="center" rowspan="1" colspan="1">568 (37.9%)</td><td align="center" rowspan="1" colspan="1">152 (38.5%)</td><td align="center" rowspan="1" colspan="1">309 (39.5%)</td><td align="center" rowspan="1" colspan="1">107 (33.2%)</td></tr><tr><td align="center" rowspan="1" colspan="1">Active smoker</td><td align="center" rowspan="1" colspan="1">313 (20.9%)</td><td align="center" rowspan="1" colspan="1">108 (27.3%)</td><td align="center" rowspan="1" colspan="1">143 (18.3%)</td><td align="center" rowspan="1" colspan="1">62 (19.3%)</td></tr><tr><td rowspan="1" colspan="1">Alcohol, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">167 (11.1%)</td><td align="center" rowspan="1" colspan="1">46 (11.6%)</td><td align="center" rowspan="1" colspan="1">97 (12.4%)</td><td align="center" rowspan="1" colspan="1">24 (7.4%)</td><td align="center" rowspan="1" colspan="1">0.056</td></tr><tr><td rowspan="1" colspan="1">History of COVID-19, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">608 (40.5%)</td><td align="center" rowspan="1" colspan="1">160 (40.5%)</td><td align="center" rowspan="1" colspan="1">343 (43.8%)</td><td align="center" rowspan="1" colspan="1">105 (32.6%)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn id="TFN1001"><p>Categorical variables (%) and continuous variables presented frequently are shown as median and interquartile range. DAPT: Dual antiplatelet therapy; STEMI: ST-elevation myocardial infarction; NSTE-ACS: Non-ST-segment elevation acute coronary syndrome; CCS: Chronic coronary syndromes; CAD: coronary artery disease; CABG: coronary artery bypass graft; COPD: Chronic obstructive pulmonary disease; TIA: transient ischemic attack; BMI: body mass index; COVID-19: Coronavirus disease 2019.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap position="float" id="t2001" orientation="portrait"><label>Table 2</label><caption><title>&#8211; Clinical features and concomitant drug treatments of the study patients</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">Total n=1500</th><th rowspan="1" colspan="1">STEMI n=395</th><th rowspan="1" colspan="1">NSTE-ACS n=783</th><th rowspan="1" colspan="1">CCS n=322</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">130 (120 &#8211; 142)</td><td align="center" rowspan="1" colspan="1">130 (119 &#8211; 140)</td><td align="center" rowspan="1" colspan="1">130 (120 &#8211; 145)</td><td align="center" rowspan="1" colspan="1">130 (119 &#8211; 140)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">Diastolic blood pressure, mm Hg</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">80 (70 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">78 (70 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">80 (71 &#8211; 88)</td><td align="center" rowspan="1" colspan="1">78 (70 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Heart rate, pulse/min</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">75 (68 &#8211; 84)</td><td align="center" rowspan="1" colspan="1">75 (68 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">77 (69 &#8211; 85)</td><td align="center" rowspan="1" colspan="1">74 (66 &#8211; 81)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">PRECISE-DAPT score</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">15 (8 &#8211; 23)</td><td align="center" rowspan="1" colspan="1">13 (7 &#8211; 22)</td><td align="center" rowspan="1" colspan="1">15 (8 &#8211; 24)</td><td align="center" rowspan="1" colspan="1">15 (8 &#8211; 24)</td><td align="center" rowspan="1" colspan="1">0.128</td></tr><tr><td rowspan="1" colspan="1">DAPT score</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">2 (1 &#8211; 3)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Hemoglobin, g/dL</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">13.7 (12.2 &#8211; 14.9)</td><td align="center" rowspan="1" colspan="1">14.0 (12.6 &#8211; 15.0)</td><td align="center" rowspan="1" colspan="1">13.6 (12.1 &#8211; 14.8)</td><td align="center" rowspan="1" colspan="1">13.6 (12.0 &#8211; 14.6)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">LDL-cholesterol, mg/dL</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">110 (85 &#8211; 137)</td><td align="center" rowspan="1" colspan="1">113 (89 &#8211; 138)</td><td align="center" rowspan="1" colspan="1">111 (86 &#8211; 138)</td><td align="center" rowspan="1" colspan="1">106 (77 &#8211; 135)</td><td align="center" rowspan="1" colspan="1">0.030</td></tr><tr><td rowspan="3" colspan="1">Left ventricular ejection fraction, n (%)</td><td align="center" rowspan="1" colspan="1">&lt;%40</td><td align="center" rowspan="1" colspan="1">152 (10.1%)</td><td align="center" rowspan="1" colspan="1">53 (13.4%)</td><td align="center" rowspan="1" colspan="1">82 (10.5%)</td><td align="center" rowspan="1" colspan="1">17 (5.3%)</td><td align="center" rowspan="3" colspan="1">&lt;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">%40-49</td><td align="center" rowspan="1" colspan="1">340 (22.7%)</td><td align="center" rowspan="1" colspan="1">120 (30.4%)</td><td align="center" rowspan="1" colspan="1">162 (20.7%)</td><td align="center" rowspan="1" colspan="1">58 (18%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8805;%50</td><td align="center" rowspan="1" colspan="1">1008 (67.2%)</td><td align="center" rowspan="1" colspan="1">222 (56.2%)</td><td align="center" rowspan="1" colspan="1">539 (68.8%)</td><td align="center" rowspan="1" colspan="1">247 (76.7%)</td></tr><tr><td rowspan="1" colspan="1">CIED, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">24 (1.6%)</td><td align="center" rowspan="1" colspan="1">3 (0.8%)</td><td align="center" rowspan="1" colspan="1">19 (2.4%)</td><td align="center" rowspan="1" colspan="1">2 (0.6%)</td><td align="center" rowspan="1" colspan="1">0.021</td></tr><tr><td rowspan="1" colspan="1"><bold>Concurrent drug treatment</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Betablocker, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1310 (87.3%)</td><td align="center" rowspan="1" colspan="1">337 (85.3%)</td><td align="center" rowspan="1" colspan="1">688 (87.9%)</td><td align="center" rowspan="1" colspan="1">285 (88.5%)</td><td align="center" rowspan="1" colspan="1">0.358</td></tr><tr><td rowspan="1" colspan="1">ACEI or ARB, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1155 (77.0%)</td><td align="center" rowspan="1" colspan="1">316 (80%)</td><td align="center" rowspan="1" colspan="1">607 (77.5%)</td><td align="center" rowspan="1" colspan="1">232 (72%)</td><td align="center" rowspan="1" colspan="1">0.037</td></tr><tr><td rowspan="1" colspan="1">ARNI, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">14 (0.9%)</td><td align="center" rowspan="1" colspan="1">2 (0.5%)</td><td align="center" rowspan="1" colspan="1">11 (1.4%)</td><td align="center" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" rowspan="1" colspan="1">0.135</td></tr><tr><td rowspan="1" colspan="1">SGLT-2 inhibitors, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">138 (9.2%)</td><td align="center" rowspan="1" colspan="1">42 (10.6%)</td><td align="center" rowspan="1" colspan="1">62 (7.9%)</td><td align="center" rowspan="1" colspan="1">34 (10.6%)</td><td align="center" rowspan="1" colspan="1">0.200</td></tr><tr><td rowspan="1" colspan="1">High-moderate intensity statins, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1244 (82.9%)</td><td align="center" rowspan="1" colspan="1">326 (82.5%)</td><td align="center" rowspan="1" colspan="1">650 (83.0%)</td><td align="center" rowspan="1" colspan="1">268 (83.2%)</td><td align="center" rowspan="1" colspan="1">0.966</td></tr><tr><td rowspan="1" colspan="1">Calcium channel blockers, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">169 (11.3%)</td><td align="center" rowspan="1" colspan="1">39 (9.9%)</td><td align="center" rowspan="1" colspan="1">101 (18.3%)</td><td align="center" rowspan="1" colspan="1">29 (9%)</td><td align="center" rowspan="1" colspan="1">0.105</td></tr><tr><td rowspan="1" colspan="1">Nitrates, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">245 (16.3%)</td><td align="center" rowspan="1" colspan="1">59 (14.9%)</td><td align="center" rowspan="1" colspan="1">143 (18.3%)</td><td align="center" rowspan="1" colspan="1">43 (13.4%)</td><td align="center" rowspan="1" colspan="1">0.091</td></tr><tr><td rowspan="1" colspan="1">Ranolazine, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">225 (15.0%)</td><td align="center" rowspan="1" colspan="1">51 (12.9%)</td><td align="center" rowspan="1" colspan="1">132 (16.9%)</td><td align="center" rowspan="1" colspan="1">42 (13%)</td><td align="center" rowspan="1" colspan="1">0.109</td></tr><tr><td rowspan="1" colspan="1">Trimetazidine, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">265 (17.7%)</td><td align="center" rowspan="1" colspan="1">60 (15.2%)</td><td align="center" rowspan="1" colspan="1">145 (18.5%)</td><td align="center" rowspan="1" colspan="1">60 (18.6%)</td><td align="center" rowspan="1" colspan="1">0.322</td></tr><tr><td rowspan="1" colspan="1">Ivabradine, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">40 (2.7%)</td><td align="center" rowspan="1" colspan="1">19 (4.8%)</td><td align="center" rowspan="1" colspan="1">15 (1.9%)</td><td align="center" rowspan="1" colspan="1">6 (1.9%)</td><td align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td rowspan="1" colspan="1">MRAs, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">163 (10.9%)</td><td align="center" rowspan="1" colspan="1">61 (15.4%)</td><td align="center" rowspan="1" colspan="1">84 (10.7%)</td><td align="center" rowspan="1" colspan="1">18 (5.6%)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">PPI, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">1174 (78.3%)</td><td align="center" rowspan="1" colspan="1">303 (76.7%)</td><td align="center" rowspan="1" colspan="1">607 (77.5%)</td><td align="center" rowspan="1" colspan="1">264 (82%)</td><td align="center" rowspan="1" colspan="1">0.179</td></tr></tbody></table><table-wrap-foot><fn id="TFN2001"><p>Categorical variables (%) and continuous variables presented frequently as median and interquartile ranges. DAPT: Dual antiplatelet therapy; LDL: low-density lipoprotein; CIED: cardiac implantable electronic devices; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor/neprilysin inhibitor; SGLT-2: sodium-glucose co-transporter-2; MRAs: mineralocorticoid receptor antagonists; PPI: proton pump inhibitor.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap position="float" id="t3001" orientation="portrait"><label>Table 3</label><caption><title>Primary and secondary endpoints</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#160;</th><th align="left" rowspan="1" colspan="1">Total n=1500</th><th align="left" rowspan="1" colspan="1">STEMI n=395</th><th align="left" rowspan="1" colspan="1">NSTE-ACS n=783</th><th align="left" rowspan="1" colspan="1">CCS n=322</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Primary endpoints</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Hospitalization for any reason, n (%)</td><td rowspan="1" colspan="1">193 (12.9%)</td><td rowspan="1" colspan="1">53 (13.4%)</td><td rowspan="1" colspan="1">108 (13.8%)</td><td rowspan="1" colspan="1">32 (9.9%)</td><td rowspan="1" colspan="1">0.205</td></tr><tr><td rowspan="1" colspan="1">Hospitalization for cardiovascular cause, n (%)</td><td rowspan="1" colspan="1">118 (7.9%)</td><td rowspan="1" colspan="1">31 (7.8%)</td><td rowspan="1" colspan="1">63 (8%)</td><td rowspan="1" colspan="1">24 (7.5%)</td><td rowspan="1" colspan="1">0.946</td></tr><tr><td rowspan="1" colspan="1">Acute myocardial infarction, n (%)</td><td rowspan="1" colspan="1">34 (2.3%)</td><td rowspan="1" colspan="1">9 (2.3%)</td><td rowspan="1" colspan="1">20 (2.6%)</td><td rowspan="1" colspan="1">5 (1.6%)</td><td rowspan="1" colspan="1">0.573</td></tr><tr><td rowspan="1" colspan="1">Stent thrombosis, n (%)</td><td rowspan="1" colspan="1">20 (1.3%)</td><td rowspan="1" colspan="1">9 (2.3%)</td><td rowspan="1" colspan="1">9 (1.2%)</td><td rowspan="1" colspan="1">2 (0.6%)</td><td rowspan="1" colspan="1">0.127</td></tr><tr><td rowspan="1" colspan="1">Target vessel revascularization, n (%)</td><td rowspan="1" colspan="1">63 (4.2%)</td><td rowspan="1" colspan="1">21 (5.3%)</td><td rowspan="1" colspan="1">34 (4.3%)</td><td rowspan="1" colspan="1">8 (2.5%)</td><td rowspan="1" colspan="1">0.141</td></tr><tr><td rowspan="1" colspan="1">BARC type 1 bleeding, n (%)</td><td rowspan="1" colspan="1">50 (3.3%)</td><td rowspan="1" colspan="1">13 (3.3%)</td><td rowspan="1" colspan="1">25 (3.2%)</td><td rowspan="1" colspan="1">12 (3.7%)</td><td rowspan="1" colspan="1">0.905</td></tr><tr><td rowspan="1" colspan="1">BARC type 5, 3, or 2 bleeding, n (%)</td><td rowspan="1" colspan="1">8 (0.6%)</td><td rowspan="1" colspan="1">1 (0.3%)</td><td rowspan="1" colspan="1">5 (0.6%)</td><td rowspan="1" colspan="1">2 (0.6%)</td><td rowspan="1" colspan="1">0.672</td></tr><tr><td rowspan="1" colspan="1"><bold>Secondary endpoints</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Death for any reason, n (%)</td><td rowspan="1" colspan="1">8 (0.5%)</td><td rowspan="1" colspan="1">3 (0.8%)</td><td rowspan="1" colspan="1">3 (0.4%)</td><td rowspan="1" colspan="1">2 (0.6%)</td><td rowspan="1" colspan="1">0.684</td></tr><tr><td rowspan="1" colspan="1">Death from cardiovascular cause, n (%)</td><td rowspan="1" colspan="1">5 (0.3%)</td><td rowspan="1" colspan="1">2 (0.5%)</td><td rowspan="1" colspan="1">2 (0.3%)</td><td rowspan="1" colspan="1">1 (0.3%)</td><td rowspan="1" colspan="1">0.777</td></tr><tr><td rowspan="1" colspan="1">Stroke, n (%)</td><td rowspan="1" colspan="1">5 (0.3%)</td><td rowspan="1" colspan="1">2 (0.5%)</td><td rowspan="1" colspan="1">3 (0.4%)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.474</td></tr></tbody></table><table-wrap-foot><fn id="TFN3001"><p>Values in parentheses are percentages. BARC: Bleeding Academic Research Consortium.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In patients undergoing medical treatment or PCI for STEMI, NSTE-ACS or CCS, current guidelines have shown that the addition of P2Y12 inhibitors (ticagrelor, prasugrel or clopidogrel) to ASA for appropriate periods has favourable effects on mortality.<sup><xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B5" ref-type="bibr">5</xref></sup> The combination of ischaemic burden and bleeding risk is crucial in choosing the DAPT and how long it should be continued. Advanced age, presence of ACS, diabetes mellitus, chronic renal failure, angiographic features and high ischaemic risk score (SYNTAX 2, GRACE, TIMI, DAPT) should be considered in the evaluation of ischaemic burden. In the assessment of bleeding risk, history of major bleeding, history of stroke, anaemia, decreased platelet count, malignancy, advanced age, severe liver disease, anticoagulant drug use and high bleeding risk score (ARC-HBR, PRECISE-DAPT) should be considered. DAPT treatment is given by taking into account the recommendations of the current guidelines in a way to balance ischaemic burden, which is an efficacy indicator, and bleeding risk, which is an safety indicator. Fixed- dose combination (ASA 75 mg + clopidogrel 75 mg) treatment was effective and safe in eligible patients with acute or CCSs. In the CURE study, which observed the effects of ASA dose when used alone or in combination with clopidogrel in patients with acute coronary syndrome, higher ASA doses (&gt;100 mg) led to higher bleeding complication rates with lack of additional efficacy.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> In atherosclerotic cardiovascular disease, current data recommend a daily ASA dose in the range of 75 to 100 mg. In France, in a study of 380 patients, ASA 75 mg and clopidogrel separately or in fixed-dose combination therapy was shown to improve patient drug compliance, but was not evaluated in terms of efficacy and safety.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Our study is the first prospective, multicentre, observational study to investigate the safety and efficacy of fixed dose combination (ASA 75 mg + clopidogrel 75 mg) DAPT in these patients.</p><p>Regarding the primary endpoints, the rate of hospitalization for cardiovascular reasons including heart failure, acute MI, stent thrombosis and rhythm disorders such as atrial fibrillation or ventricular tachycardia was 7.9%. Chronologically, ASA alone, followed by DAPT with ASA and clopidogrel, and finally ASA with ticagroler and/or prasugrel, more potent inhibitors of the adenosine diphosphate receptor P2Y12, have been shown to reduce the risk of myocardial ischaemic events in patients with acute coronary syndrome.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Prospective studies involving patients with acute coronary syndromes or patients undergoing PCI in which clopidogrel therapy was used showed differences in terms of primary endpoints. When we look at the studies conducted on acute coronary syndrome patients, in the TRITON-TIMI 38 study,<sup><xref rid="B11" ref-type="bibr">11</xref></sup> MI was found in 9.7% of patients in the group receiving clopidogrel treatment.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> In the CLARITY-TIMI 28 study,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> the rate of repeat MI in the clopidogrel arm was 2.5%,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> and in the CURE study,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> the rate of MI was 5.2% in 6,259 patients using clopidogrel.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> In the CURRENT-OASIS 7 study,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> the MI rate was 2% in the double dose group and 2.6% in the standard dose group,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> and in the PLATO study, the MI rate was 6.9% in the clopidogrel arm.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> As can be seen, although the MI rate varies in acute coronary syndrome studies using clopidogrel treatment, in our study, this rate was low as 2.3% in the entire population and 2.3% and 2.6% in the STEMI and NSTE-ACS groups, respectively. With respect to studies conducted on CCS patients, in the EXCELLENT study,<sup><xref rid="B16" ref-type="bibr">16</xref></sup> MI was observed in 1.8% of 722 patients in the six-month treatment group.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> In the PRODIGY study,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> MI rate was 4.2% in the short-term DAPT (six months) group, and in CREDO study,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> MI occurred in 6.6% of patients in the clopidogrel arm of 1,053 patients.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> In a meta-analysis of 10 randomised controlled trials on optimal duration of DAPT after PCI with drug-eluting stents, the MI rate was 1.6% in the short-term treatment group.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> Therefore, although the MI rate varies in various studies using clopidogrel treatment, this rate was found to be low as 1.6% in the CCS subgroup.</p><p>In a multicentric, prospective study, Oh et al.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> investigated the platelet inhibition potential of fixed dose combination of ASA plus clopidogrel and compared with seperate doses in patients who had undergone PCI with drug-eluting stent. The authors demonstrated that the efficacy of platelet inhibition by fixed-dose combination was not different than that of seperate doses of ASA and clopidogrel, with no serious cardiovascular adverse events.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> Additionally, in a randomized study, Choi et al.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> showed that the pharmacokinetic characteristics of fixed-dose combination of ASA and clopidogrel were bioequivalent to that of seperate administiration of each drug. These pharmacokinetic features may explain the efficacy of fixed-dose combination therapy on clinical endpoints as compared with the administration of the drugs separately.<sup><xref rid="B21" ref-type="bibr">21</xref></sup></p><p>When we look at stent thrombosis, which is evaluated as another efficacy indicator, different rates have been reported among the studies, mainly due to variations in stent thrombosis definition and patient selection. In the PLATO study,<sup><xref rid="B15" ref-type="bibr">15</xref></sup> stent thrombosis occurred in 1.9% in the clopidogrel arm. In the TRITON-TIMI 38 study,<sup><xref rid="B11" ref-type="bibr">11</xref></sup> the rate of definite and probable stent thrombosis in the clopidogrel group was 2.4%. In the CURRENT-OASIS 7<sup><xref rid="B14" ref-type="bibr">14</xref></sup> study with a short follow-up period of 28 days, the rate of definite stent thrombosis was 0.7% in the double-dose group and 1.3% in the standard-dose group.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> Although the stent thrombosis rate varies in ACS studies, in our study this rate was 1.3% in all patients, while it was 2.3% and 1.2% in the STEMI and NSTE-ACS subgroups, respectively. In the EXCELLENT<sup><xref rid="B16" ref-type="bibr">16</xref></sup> and PRODIGY<sup><xref rid="B17" ref-type="bibr">17</xref></sup> studies, definite and probable stent thrombosis in the six-month DAPT arms were 0.9% and 1.5%, respectively. In a meta-analysis of 10 studies using clopidogrel after drug-eluting stents in CCS patients, the rate of stent thrombosis was found to be 0.52%.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> In our study, the rate of definite stent thrombosis was 0.6% in the CCS subgroup. While the rate of urgent TVR was 3.7% in the TRITON-TIMI 38 study,<sup><xref rid="B11" ref-type="bibr">11</xref></sup> revascularization after randomization was 11.5% in the CURE study,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> any TVR was 13.1% in the CREDO study.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> In our study, the TVR rate was 4.2%. These significant differences between the studies may be due to various factors such as the selected stent structure, comorbidities, and follow-up period.</p><p>Regarding the secondary endpoint, the rate of stroke was 0.3% in our study. In the CHARISMA study,<sup><xref rid="B22" ref-type="bibr">22</xref></sup> the PLATO study,<sup><xref rid="B15" ref-type="bibr">15</xref></sup> the CURE study<sup><xref rid="B13" ref-type="bibr">13</xref></sup> and the CREDO study,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> stroke rates were 1.9%, 1.3%, 1.2% and 0.9%, respectively. We believe such variation is due to different characteristics of the study populations.</p><p>Bleeding is used for safety endpoint evaluation of antiplatelet, antiaggregant and anticoagulant therapies. Various bleeding classifications such as The Thrombolysis in Myocardial Infarction (TIMI) bleeding, BARC, REPLACE-2 and GUSTO have been used in studies.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> In the CLARITY-TIMI 28 study,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> the rates of major bleeding (TIMI) was 1.9% and minor bleeding was 1.3% in the PCI group.<sup><xref rid="B12" ref-type="bibr">12</xref></sup> In the TRITON-TIMI 38 study, non-CABG-related TIMI major bleeding was 1.8% in the clopidogrel group.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> In the CURRENT-OASIS 7 study,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> the rates of CURRENT-defined major and severe bleeding was 2.7% in the double-dose group and 1.9% in the standard-dose group. In the EXCELENT study,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> TIMI major bleeding rate was 0.3% in the short-term DAPT group.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> In the PRODIGY study,<sup><xref rid="B17" ref-type="bibr">17</xref></sup> the rate of BARC type 5, 3, or 2 was 3.5% and of TIMI major bleeding was 0.6% in the six-month DAPT group.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> In the CREDO study,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> the rate of nonprocedural TIMI major bleeding was 1.2% in the clopidogrel arm. In our study, we used the BARC classification, and the rates of BARC type 1 was 3.3%, while BARC type 5, 3, or 2 was 0.6%. In the STEMI subgroup, BARC type 1 is 3.3%, BARC type 5, 3 or 2 is 0.3%; in the NSTE-ACS subgroup, BARC type 1 is 3.2%, BARC type 5, 3 or 2 is 0.6%, and in the CCS subgroup, BARC type 1 was found to be 3.7%, and BARC types 5, 3 or 2 was found to be 0.6%. It suggests that the differences between the studies may be due to the inclusion and exclusion criteria. Jung et al.<sup><xref rid="B23" ref-type="bibr">23</xref></sup> assessed the safety profile of fixed dose combination in a randomized trial. There was no serious adverse events or death in study population.</p><sec><title>Study limitations</title><p>The first limitation of our study is the lack of studies comparing other DAPT treatments or ASA and clopidogrel treatments separately. The second is the inclusion of diseases that may pose a high risk for bleeding in the patient exclusion criteria.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Our study demonstrates that fixed-dose combination DAPT is effective and safe in patients with ACS or CCS, appropriately selected based on their ischaemic burden and bleeding risk.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Study association:</bold> This study is not associated with any thesis or dissertation work.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This study was approved by the Ethics Committee of the Istanbul Training and Research Hospital under the protocol number 2990. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of funding:</bold> There were no external funding sources for this study.</p></fn></fn-group></back></sub-article></article></pmc-articleset>